CA3149681A1 - A method and a compound for preventing mammalian cancer cell proliferation and for treating cancer - Google Patents
A method and a compound for preventing mammalian cancer cell proliferation and for treating cancer Download PDFInfo
- Publication number
- CA3149681A1 CA3149681A1 CA3149681A CA3149681A CA3149681A1 CA 3149681 A1 CA3149681 A1 CA 3149681A1 CA 3149681 A CA3149681 A CA 3149681A CA 3149681 A CA3149681 A CA 3149681A CA 3149681 A1 CA3149681 A1 CA 3149681A1
- Authority
- CA
- Canada
- Prior art keywords
- lignan
- extract
- composition
- mixture
- extracts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 77
- 201000011510 cancer Diseases 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 49
- 230000009702 cancer cell proliferation Effects 0.000 title claims abstract description 32
- 150000001875 compounds Chemical class 0.000 title description 6
- 229930013686 lignan Natural products 0.000 claims abstract description 258
- 235000009408 lignans Nutrition 0.000 claims abstract description 258
- 150000005692 lignans Chemical class 0.000 claims abstract description 258
- 239000000284 extract Substances 0.000 claims abstract description 254
- 239000000203 mixture Substances 0.000 claims abstract description 233
- SLJTWDNVZKIDAU-SVAFSPIFSA-N Betulonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C SLJTWDNVZKIDAU-SVAFSPIFSA-N 0.000 claims abstract description 98
- SLJTWDNVZKIDAU-CKURCAGRSA-N Betulonic acid Natural products CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@@H](CC[C@@H]4[C@@]5(C)CCC(=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O SLJTWDNVZKIDAU-CKURCAGRSA-N 0.000 claims abstract description 98
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 claims abstract description 98
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 claims abstract description 97
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 claims abstract description 97
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 claims abstract description 97
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 claims abstract description 97
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 claims abstract description 97
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 81
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 80
- 238000011282 treatment Methods 0.000 claims abstract description 66
- 201000001441 melanoma Diseases 0.000 claims abstract description 43
- 241000894007 species Species 0.000 claims abstract description 43
- 230000035755 proliferation Effects 0.000 claims abstract description 37
- 238000000338 in vitro Methods 0.000 claims abstract description 26
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 23
- 210000002307 prostate Anatomy 0.000 claims abstract description 18
- 230000012010 growth Effects 0.000 claims abstract description 17
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 14
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 14
- 208000003174 Brain Neoplasms Diseases 0.000 claims abstract description 13
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 13
- 230000002195 synergetic effect Effects 0.000 claims abstract description 10
- 241000218657 Picea Species 0.000 claims description 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 35
- 241000218642 Abies Species 0.000 claims description 29
- 230000005907 cancer growth Effects 0.000 claims description 28
- MHXCIKYXNYCMHY-AUSJPIAWSA-N (+)-lariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@@H]([C@H](OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 MHXCIKYXNYCMHY-AUSJPIAWSA-N 0.000 claims description 26
- YHYNYYXJMLXPRQ-NILVNCKXSA-N 4-[hydroxy-[(3r,4r)-4-[hydroxy-(4-hydroxy-3-methoxyphenyl)methyl]oxolan-3-yl]methyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C(O)[C@@H]2[C@H](COC2)C(O)C=2C=C(OC)C(O)=CC=2)=C1 YHYNYYXJMLXPRQ-NILVNCKXSA-N 0.000 claims description 26
- YVRYZXAHRGGELT-UHFFFAOYSA-N Lariciresinol Natural products C1=C2OCOC2=CC(C2C(C)C3(OC)C=C(CC=C)C(=O)CC3(O2)OC)=C1 YVRYZXAHRGGELT-UHFFFAOYSA-N 0.000 claims description 26
- UKHWOLNMBQSCLJ-BIENJYKASA-N hydroxymatairesinol Chemical compound C1=C(O)C(OC)=CC(C[C@H]2C(OC[C@@H]2[C@H](O)C=2C=C(OC)C(O)=CC=2)=O)=C1 UKHWOLNMBQSCLJ-BIENJYKASA-N 0.000 claims description 26
- 235000006826 lariciresinol Nutrition 0.000 claims description 26
- YHYNYYXJMLXPRQ-UHFFFAOYSA-N liovil Natural products C1=C(O)C(OC)=CC(C(O)C2C(COC2)C(O)C=2C=C(OC)C(O)=CC=2)=C1 YHYNYYXJMLXPRQ-UHFFFAOYSA-N 0.000 claims description 26
- PUETUDUXMCLALY-HOTGVXAUSA-N (-)-secoisolariciresinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 PUETUDUXMCLALY-HOTGVXAUSA-N 0.000 claims description 25
- OGFXBIXJCWAUCH-UHFFFAOYSA-N meso-secoisolariciresinol Natural products C1=2C=C(O)C(OC)=CC=2CC(CO)C(CO)C1C1=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-UHFFFAOYSA-N 0.000 claims description 25
- 235000004239 secoisolariciresinol Nutrition 0.000 claims description 25
- ZZSOKNNVDKKSDE-UHFFFAOYSA-N 7-hydroxymatairesinol Natural products C1=C(O)C(OC)=CC(CC2C(C(=O)OC2)C(O)C=2C=C(OC)C(O)=CC=2)=C1 ZZSOKNNVDKKSDE-UHFFFAOYSA-N 0.000 claims description 24
- 235000005205 Pinus Nutrition 0.000 claims description 24
- 241000218602 Pinus <genus> Species 0.000 claims description 24
- CAYMSCGTKZIVTN-TYILLQQXSA-N alpha-Conidendrin Chemical compound C1([C@@H]2[C@@H]3[C@H](C(OC3)=O)CC=3C=C(C(=CC=32)O)OC)=CC=C(O)C(OC)=C1 CAYMSCGTKZIVTN-TYILLQQXSA-N 0.000 claims description 24
- CAYMSCGTKZIVTN-UHFFFAOYSA-N alpha-conidendrin Natural products C1=2C=C(O)C(OC)=CC=2CC(C(OC2)=O)C2C1C1=CC=C(O)C(OC)=C1 CAYMSCGTKZIVTN-UHFFFAOYSA-N 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 22
- 235000010140 Betula sp Nutrition 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 claims description 5
- MATGKVZWFZHCLI-LSDHHAIUSA-N (-)-matairesinol Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(OC)C(O)=CC=2)=C1 MATGKVZWFZHCLI-LSDHHAIUSA-N 0.000 claims description 5
- 235000009109 Betula pendula Nutrition 0.000 claims description 5
- 241000219430 Betula pendula Species 0.000 claims description 5
- 235000000055 matairesinol Nutrition 0.000 claims description 5
- RNXYRAQIZQGUIK-UHFFFAOYSA-N matairesinol Natural products COc1cc(CC2OCC(=O)C2Cc3ccc(O)c(OC)c3)ccc1O RNXYRAQIZQGUIK-UHFFFAOYSA-N 0.000 claims description 5
- 235000007221 pinoresinol Nutrition 0.000 claims description 5
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 claims description 5
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 claims description 5
- ZITBJWXLODLDRH-UHFFFAOYSA-N (+)--Wikstromol Natural products C1=C(O)C(OC)=CC(CC2C(C(=O)OC2)(O)CC=2C=C(OC)C(O)=CC=2)=C1 ZITBJWXLODLDRH-UHFFFAOYSA-N 0.000 claims description 4
- ZITBJWXLODLDRH-XOBRGWDASA-N Nortrachelogenin Chemical compound C1=C(O)C(OC)=CC(C[C@@H]2[C@@](C(=O)OC2)(O)CC=2C=C(OC)C(O)=CC=2)=C1 ZITBJWXLODLDRH-XOBRGWDASA-N 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- -1 condendrin Chemical compound 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 4
- YNOCUODOFOEIFZ-UHFFFAOYSA-N Hydroxymatairesinol Natural products C1=C(O)C(OC)=CC=C1CC1C(=O)OCC1C(O)C1=CC=C(OC)C(O)=C1 YNOCUODOFOEIFZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000028990 Skin injury Diseases 0.000 claims description 2
- 229930004725 sesquiterpene Natural products 0.000 claims description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- XZMJVNBHYBOCGF-PMACEKPBSA-N -secoisolariciresinol Natural products COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(C)c(OC)c2)ccc1C XZMJVNBHYBOCGF-PMACEKPBSA-N 0.000 claims 2
- 239000012675 alcoholic extract Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 14
- 241001465754 Metazoa Species 0.000 abstract description 5
- 230000007423 decrease Effects 0.000 abstract description 5
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 230000007541 cellular toxicity Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 187
- 239000002023 wood Substances 0.000 description 67
- 239000000243 solution Substances 0.000 description 31
- 238000000605 extraction Methods 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 230000004663 cell proliferation Effects 0.000 description 20
- 235000019441 ethanol Nutrition 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- 238000010859 live-cell imaging Methods 0.000 description 19
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 16
- 235000008124 Picea excelsa Nutrition 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 11
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000022131 cell cycle Effects 0.000 description 7
- 238000002784 cytotoxicity assay Methods 0.000 description 7
- 231100000263 cytotoxicity test Toxicity 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 235000015872 dietary supplement Nutrition 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 229930182816 L-glutamine Natural products 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 235000012570 Pinus sp Nutrition 0.000 description 6
- 125000005233 alkylalcohol group Chemical group 0.000 description 6
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 6
- 238000001543 one-way ANOVA Methods 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 235000013772 propylene glycol Nutrition 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 230000010190 G1 phase Effects 0.000 description 5
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 5
- 208000021039 metastatic melanoma Diseases 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 230000004668 G2/M phase Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000011201 multiple comparisons test Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000005456 alcohol based solvent Substances 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 229940043375 1,5-pentanediol Drugs 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- 241000219429 Betula Species 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920001131 Pulp (paper) Polymers 0.000 description 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- 239000003075 phytoestrogen Substances 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012342 propidium iodide staining Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- OGFXBIXJCWAUCH-KPHUOKFYSA-N (+)-isolariciresinol Chemical compound C1([C@@H]2[C@@H](CO)[C@H](CO)CC=3C=C(C(=CC=32)O)OC)=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-KPHUOKFYSA-N 0.000 description 1
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- FJBQYOWYDLEAKI-UHFFFAOYSA-N (2,3-dimethyl-4-phenylbutyl)benzene Chemical group C=1C=CC=CC=1CC(C)C(C)CC1=CC=CC=C1 FJBQYOWYDLEAKI-UHFFFAOYSA-N 0.000 description 1
- BVHIKUCXNBQDEM-JSNMRZPZSA-N (3s,4r,5s)-5-(4-hydroxy-3-methoxyphenyl)-3-[(4-hydroxy-3-methoxyphenyl)methyl]-4-(hydroxymethyl)oxolan-3-ol Chemical compound C1=C(O)C(OC)=CC(C[C@]2(O)[C@@H]([C@H](OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 BVHIKUCXNBQDEM-JSNMRZPZSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FGLBSLMDCBOPQK-UHFFFAOYSA-N 2-nitropropane Chemical compound CC(C)[N+]([O-])=O FGLBSLMDCBOPQK-UHFFFAOYSA-N 0.000 description 1
- 244000283070 Abies balsamea Species 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000862 Arboform Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 235000003932 Betula Nutrition 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- DWONJCNDULPHLV-HOTGVXAUSA-N Enterodiol Chemical compound C([C@@H](CO)[C@H](CO)CC=1C=C(O)C=CC=1)C1=CC=CC(O)=C1 DWONJCNDULPHLV-HOTGVXAUSA-N 0.000 description 1
- AOJXPBNHAJMETF-UHFFFAOYSA-N Enterodiol Natural products OCC(Cc1ccc(O)cc1)C(CO)Cc2ccc(O)cc2 AOJXPBNHAJMETF-UHFFFAOYSA-N 0.000 description 1
- HVDGDHBAMCBBLR-UHFFFAOYSA-N Enterolactone Natural products OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VQENOYXMFIFHCY-UHFFFAOYSA-N Monoglyceride citrate Chemical compound OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O VQENOYXMFIFHCY-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- NYDZRKZVFLLTLO-UHFFFAOYSA-N Neoolivil Natural products C1=C(O)C(OC)=CC(C2C(C(CO)C(O2)C=2C=C(OC)C(O)=CC=2)CO)=C1 NYDZRKZVFLLTLO-UHFFFAOYSA-N 0.000 description 1
- BVHIKUCXNBQDEM-UHFFFAOYSA-N Olivil Natural products C1=C(O)C(OC)=CC(CC2(O)C(C(OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 BVHIKUCXNBQDEM-UHFFFAOYSA-N 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000008582 Pinus sylvestris Nutrition 0.000 description 1
- 241000218626 Pinus sylvestris Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000006650 Syzygium cordatum Nutrition 0.000 description 1
- 240000005572 Syzygium cordatum Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 229930194930 Triterpen Natural products 0.000 description 1
- 241000218685 Tsuga Species 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000000385 effect on melanoma Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HVDGDHBAMCBBLR-WMLDXEAASA-N enterolactone Chemical compound OC1=CC=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-WMLDXEAASA-N 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- OEZZQOVAJDAVSJ-UHFFFAOYSA-N isolariciresinol Natural products COc1cc(ccc1O)C1C(CO)C(CO)Cc2cc(O)c(OC)cc12 OEZZQOVAJDAVSJ-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
- CIBMHJPPKCXONB-UHFFFAOYSA-N propane-2,2-diol Chemical compound CC(C)(O)O CIBMHJPPKCXONB-UHFFFAOYSA-N 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008171 pumpkin seed oil Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A composition and a method for use in suppressing growth and/or proliferation of cancer cells in vivo and in vitro is provided. The composition includes an alcoholic lignan extract prepared from coniferous species optionally in combination with betulonic acid or betulinic acid. The composition inhibits growth and/or proliferation of at least prostate and melanoma cancer cells in vitro. Combination of the alcoholic lignan extract and betulonic or betulinic acid has a synergic effect specifically in inhibition of melanoma and prostate cancer cell proliferation and toxicity. Oral daily administration of the composition decreases or in some cases abolishes tumors of patients with breast cancer, brain cancer or colon cancer. The composition is suitable for use in cancer treatment in pet animals as well.
Description
A METHOD AND A COMPOUND FOR PREVENTING MAMMALIAN CANCER CELL
PROLIFERATION AND FOR TREATING CANCER
Field of the invention The invention generally relates to plant lignan extracts or a mixture of lignan extracts, and methods of using such extracts in treatments of cancer.
More specifically the invention relates to lignan extracts from certain coniferous species for suppressing proliferation or growth of mammalian cancer cells as defined in the claim 1.
The invention further relates use of a composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species in a method for suppressing cancer cell proliferation and/or growth in a mammal.
The invention also relate to a method for suppressing proliferation of prostate and melanoma cancer cells in vitroõ comprising a step of adding on the prostate or melanoma cell culture a composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species.
Furthermore, the invention relates to synergistic effect of lignan extract and betulinic or betulonic acids in suppression of mammalian cancer cell proliferation.
Background of the Invention Lignans are primarily structurally defined as polyphenols, which are complex molecules composed of a plurality of phenol molecules adhered and linked together and generally possess a 2,3-dibenzylbutane structure. They include, among other compounds the following but not limited to matairesinol, conidendrin, secoisolariciresinol, lariciresinol, isolariciresinol, nordihydroguaiaretic acid, pinoresinol, liovil and olivil, pinoresinol, nortrachelogenin, matairesinol and juvabiones and other compounds, which may be precursors of enterolactone and enterodiol and modifications thereof, including diglucosides. Specific sesquiterpenes such as juvabiones may have similar physiological effects as lignans.
PROLIFERATION AND FOR TREATING CANCER
Field of the invention The invention generally relates to plant lignan extracts or a mixture of lignan extracts, and methods of using such extracts in treatments of cancer.
More specifically the invention relates to lignan extracts from certain coniferous species for suppressing proliferation or growth of mammalian cancer cells as defined in the claim 1.
The invention further relates use of a composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species in a method for suppressing cancer cell proliferation and/or growth in a mammal.
The invention also relate to a method for suppressing proliferation of prostate and melanoma cancer cells in vitroõ comprising a step of adding on the prostate or melanoma cell culture a composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species.
Furthermore, the invention relates to synergistic effect of lignan extract and betulinic or betulonic acids in suppression of mammalian cancer cell proliferation.
Background of the Invention Lignans are primarily structurally defined as polyphenols, which are complex molecules composed of a plurality of phenol molecules adhered and linked together and generally possess a 2,3-dibenzylbutane structure. They include, among other compounds the following but not limited to matairesinol, conidendrin, secoisolariciresinol, lariciresinol, isolariciresinol, nordihydroguaiaretic acid, pinoresinol, liovil and olivil, pinoresinol, nortrachelogenin, matairesinol and juvabiones and other compounds, which may be precursors of enterolactone and enterodiol and modifications thereof, including diglucosides. Specific sesquiterpenes such as juvabiones may have similar physiological effects as lignans.
2 Plant lignans are the primary source of dietary phytoestrogens in modern diet.
Phytoestrogens have multitude beneficial health-effects; high levels of lignans can support for example healthy glucose metabolism and can further reduce insulin sensitivity. Plant lignans have been suggested to be used for treating general infections and various inflammatory conditions; for example, US Patent No. 5,762,935 discloses anti-inflammatory effects of lignans from sesamin family.
However, edible plants (fruits, vegetables and seeds) contain considerably low levels of lignans, such that their health effects in normal diet is almost insignificant and hardly can be taken into account. Wood lignans, on the other hand, are abundantly found in wood material and in bark, and as such, one might consider using these lignans in the diet in the same way as plant lignans from fruits and seeds. Thus, it has been suggested to use wood lignans in food products. US patent No. 10,172,896 discloses a method to lower cholesterol level in blood serum of a mammal by orally administering a composition of lignan extract of coniferous species.
Epidemiological studies relating diet to disease suggest that dietary components may predispose populations to reduced risk of certain diseases. Far eastern populations consuming soy, for example, exhibit reduced rates of breast, prostate and colon cancers and coronary heart disease, while populations, for example, in Finland have increased rates of prostate cancer. Researchers are now just studying, and consequently, realizing the specific compounds in the diet, in order to put the puzzle together, to better understand the basis for the epidemiological observations.
Superior results may be obtainable when a plurality of phytochemicals is consumed in combinations. Therefore, a proper diet containing a combination of the desired phytochemicals, may be a desirous way to prevent various cancer forms. A
problem in today's world is that a large part of population either does not have access to proper kind of diet, or simply chooses not to follow such diet. Accordingly, there is an unmet need for dietary supplements for improving life quality of general public.
Currently, there is almost an epidemic of cancer world-wide. Traditional medical treatments include surgeries, chemotherapy, radiation, and heavy medications.
On the other hand, there is plenty of showing that many cancer forms could be prevented by lifestyle choices, including dietary choices. Accordingly, the unmet need for dietary
Phytoestrogens have multitude beneficial health-effects; high levels of lignans can support for example healthy glucose metabolism and can further reduce insulin sensitivity. Plant lignans have been suggested to be used for treating general infections and various inflammatory conditions; for example, US Patent No. 5,762,935 discloses anti-inflammatory effects of lignans from sesamin family.
However, edible plants (fruits, vegetables and seeds) contain considerably low levels of lignans, such that their health effects in normal diet is almost insignificant and hardly can be taken into account. Wood lignans, on the other hand, are abundantly found in wood material and in bark, and as such, one might consider using these lignans in the diet in the same way as plant lignans from fruits and seeds. Thus, it has been suggested to use wood lignans in food products. US patent No. 10,172,896 discloses a method to lower cholesterol level in blood serum of a mammal by orally administering a composition of lignan extract of coniferous species.
Epidemiological studies relating diet to disease suggest that dietary components may predispose populations to reduced risk of certain diseases. Far eastern populations consuming soy, for example, exhibit reduced rates of breast, prostate and colon cancers and coronary heart disease, while populations, for example, in Finland have increased rates of prostate cancer. Researchers are now just studying, and consequently, realizing the specific compounds in the diet, in order to put the puzzle together, to better understand the basis for the epidemiological observations.
Superior results may be obtainable when a plurality of phytochemicals is consumed in combinations. Therefore, a proper diet containing a combination of the desired phytochemicals, may be a desirous way to prevent various cancer forms. A
problem in today's world is that a large part of population either does not have access to proper kind of diet, or simply chooses not to follow such diet. Accordingly, there is an unmet need for dietary supplements for improving life quality of general public.
Currently, there is almost an epidemic of cancer world-wide. Traditional medical treatments include surgeries, chemotherapy, radiation, and heavy medications.
On the other hand, there is plenty of showing that many cancer forms could be prevented by lifestyle choices, including dietary choices. Accordingly, the unmet need for dietary
3 supplements for improvement of life quality is applicable also in the area of prevention and treatment of cancers of various kinds. In the modern world cancer has become common not only in human beings but also in pet animals. Accordingly, there is a further need for a dietary supplement for pet animals as well.
Summary of the Invention The invention according to this disclosure provides solutions to the above-mentioned shortcomings or at least alleviate above mentioned problems.
Therefore, it is an object of this invention to provide a composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus for use in a method for suppressing mammalian cancer cell proliferation or growth in vitro or in vivo. It is an object of this invention to provide such composition for suppressing proliferation of cancer cells in vitro and in vivo.
It is another object of this invention to provide a composition comprising mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus, together with a low concentration of betulinic or betulonic acid for use in a method for improved suppression mammalian cancer cell proliferation in vitro or in vivo. It is an object of this invention to provide such composition for suppressing proliferation of melanoma cells in vitro and in vivo.
It is further an object of this invention to provide a method to suppress proliferation or growth of melanoma cells, brain cancer cells, colon cancer cells, breast cancer cells, and prostate cancer cells by orally administering a lignan extract to a mammal.
The present invention relate to a composition according to claim 1 for suppressing mammalian cancer cell proliferation or growth, the composition being a solution comprising an alcoholic lignan extract or a mixture of alcoholic lignan extracts from one or more of coniferous species selected from the group genuses consisting of Picea, Abies, and Pinus, and optionally betulonic or betulinic acid, wherein the lignan extract or mixture of lignan extracts comprises at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers and a fraction containing various oligolignans..
Summary of the Invention The invention according to this disclosure provides solutions to the above-mentioned shortcomings or at least alleviate above mentioned problems.
Therefore, it is an object of this invention to provide a composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus for use in a method for suppressing mammalian cancer cell proliferation or growth in vitro or in vivo. It is an object of this invention to provide such composition for suppressing proliferation of cancer cells in vitro and in vivo.
It is another object of this invention to provide a composition comprising mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus, together with a low concentration of betulinic or betulonic acid for use in a method for improved suppression mammalian cancer cell proliferation in vitro or in vivo. It is an object of this invention to provide such composition for suppressing proliferation of melanoma cells in vitro and in vivo.
It is further an object of this invention to provide a method to suppress proliferation or growth of melanoma cells, brain cancer cells, colon cancer cells, breast cancer cells, and prostate cancer cells by orally administering a lignan extract to a mammal.
The present invention relate to a composition according to claim 1 for suppressing mammalian cancer cell proliferation or growth, the composition being a solution comprising an alcoholic lignan extract or a mixture of alcoholic lignan extracts from one or more of coniferous species selected from the group genuses consisting of Picea, Abies, and Pinus, and optionally betulonic or betulinic acid, wherein the lignan extract or mixture of lignan extracts comprises at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers and a fraction containing various oligolignans..
4 The present invention relate also to use of a composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from the group of genus consisting of Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid from bark of Betula sp. in a method for suppressing cancer cell proliferation and/or growth in a mammal, wherein said extract or mixture of extracts comprises at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers and a fraction containing various oligolignans.
Particularly present invention relate to the use of a composition comprising a lignan .. extract or a mixture of lignan extracts from one or more of coniferous species selected from the group of genus consisting of Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid in a method for suppressing cancer cell proliferation and/or growth in a mammal, wherein said extract or mixture of extracts comprises at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or .. their geometric isomers or stereoisomers, as well as a fraction containing various oligolignans.
The present invention is based on the surprising observation that a certain mixture of lignans in an extract, including at least: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers thereof, as well .. as a fraction containing various oligolignans, has a suppressing effect on the proliferation or growth of human prostate and melanoma cancer cells, in vitro.
Further studies showed that the suppression specifically took place during the phase of the cell cycle.
This observation was then applied to preparation of a supplement for oral use of human beings as well as pet animals. The results showed that daily intake of the composition indeed reduced existing tumors and in some cases completely abolished the tumors resulting the patients to get 'clean papers' from their doctors.
A further surprising result of experiments was that betulonic or betulinic acid in low concentrations had a synergistic effect with the lignan extract in suppressing the .. proliferation of growth of human prostate and melanoma cancer cells in vitro. Adding betulinic or betulonic acid into the preparation of the lignan mixture supplement is expected to have at least as good and likely better effect on reducing existing tumors as the lignan mixture supplement alone.
The various particular embodiments of the present invention are surprising, because the combination of a mixture of wood lignans and oligolignans, has not been known to have
Particularly present invention relate to the use of a composition comprising a lignan .. extract or a mixture of lignan extracts from one or more of coniferous species selected from the group of genus consisting of Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid in a method for suppressing cancer cell proliferation and/or growth in a mammal, wherein said extract or mixture of extracts comprises at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or .. their geometric isomers or stereoisomers, as well as a fraction containing various oligolignans.
The present invention is based on the surprising observation that a certain mixture of lignans in an extract, including at least: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers thereof, as well .. as a fraction containing various oligolignans, has a suppressing effect on the proliferation or growth of human prostate and melanoma cancer cells, in vitro.
Further studies showed that the suppression specifically took place during the phase of the cell cycle.
This observation was then applied to preparation of a supplement for oral use of human beings as well as pet animals. The results showed that daily intake of the composition indeed reduced existing tumors and in some cases completely abolished the tumors resulting the patients to get 'clean papers' from their doctors.
A further surprising result of experiments was that betulonic or betulinic acid in low concentrations had a synergistic effect with the lignan extract in suppressing the .. proliferation of growth of human prostate and melanoma cancer cells in vitro. Adding betulinic or betulonic acid into the preparation of the lignan mixture supplement is expected to have at least as good and likely better effect on reducing existing tumors as the lignan mixture supplement alone.
The various particular embodiments of the present invention are surprising, because the combination of a mixture of wood lignans and oligolignans, has not been known to have
5 an effect on the proliferation and growth of cancer cells in vitro, nor has it been suggested that use of a mixture of wood lignans and oligolignans could be used in methods to abolish tumor growth in mammals. Even if there are some studies showing betulonic and betulinic acid derivatives having effects on cancer cells, the strong synergistic effect of the lignan mixture and betulonic or betulinic acid reducing growth rate of cancer cells has never been reported.
The invention relate also a composition for use in a method for suppressing mammalian cancer cell proliferation or growth in vitro, wherein the composition comprises 5-50 wt%
of the lignan extract and proportion of said lignans in the lignan extract is:
hydroxymatairesinol 70-80 wt%; conidendrin 3-8 wt%; lariciresinol 1-4 wt%;
liovil 2-5 wt%;
secoisolariciresinol 3-7 wt%; and other lignans 0-3 wt%, wherein the fraction of other lignans includes various oligolignans, and optionally betulinic acid or betulonic acid.
The invention relate further relate to a composition comprising a lignan extract and optionally betulonic acid or betulinic acid for use in a method to suppress cancer cell proliferation or growth in a mammal having diagnosed with melanoma, a brain cancer tumor, a colon cancer tumor, a breast cancer tumor, or a prostate cancer tumor.
The composition can also be used in a method for suppressing cancer cell proliferation or growth in a mammal, said method comprising oral administration of a composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid, wherein said extract or mixture of extracts comprises at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers, as well as a fraction containing various oligolignans.
The invention also relate to a composition for use in preparing a medicament for suppressing mammalian cancer cell proliferation or growth, wherein said composition comprises a lignan extract or a mixture of lignan extracts from one or more of coniferous
The invention relate also a composition for use in a method for suppressing mammalian cancer cell proliferation or growth in vitro, wherein the composition comprises 5-50 wt%
of the lignan extract and proportion of said lignans in the lignan extract is:
hydroxymatairesinol 70-80 wt%; conidendrin 3-8 wt%; lariciresinol 1-4 wt%;
liovil 2-5 wt%;
secoisolariciresinol 3-7 wt%; and other lignans 0-3 wt%, wherein the fraction of other lignans includes various oligolignans, and optionally betulinic acid or betulonic acid.
The invention relate further relate to a composition comprising a lignan extract and optionally betulonic acid or betulinic acid for use in a method to suppress cancer cell proliferation or growth in a mammal having diagnosed with melanoma, a brain cancer tumor, a colon cancer tumor, a breast cancer tumor, or a prostate cancer tumor.
The composition can also be used in a method for suppressing cancer cell proliferation or growth in a mammal, said method comprising oral administration of a composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid, wherein said extract or mixture of extracts comprises at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers, as well as a fraction containing various oligolignans.
The invention also relate to a composition for use in preparing a medicament for suppressing mammalian cancer cell proliferation or growth, wherein said composition comprises a lignan extract or a mixture of lignan extracts from one or more of coniferous
6 species selected from genus Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid, wherein said extract or mixture of extracts comprises at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers, as well as a fraction containing various .. oligolignans.
The invention relate also a method for preparing a composition for treating melanoma or prostate cancer cells, said method comprising following steps: extracting alcoholic solution of 5-50 wt % of the lignan extract or the mixture of extracts with a lower alcohol from one or more of coniferous species selected from genus Picea, Abies, and Pinus; and admixing betulonic acid or betulinic acid preferably obtained from bark of Betula pendula into the alcoholic solution of lignan extract.
The invention provides also a method for suppressing proliferation or growth of prostate and melanoma cancer cells in vitro, comprising a step of treating said prostate and melanoma cells with a composition, comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid and comprising at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers, as well as a fraction containing various oligolignans.
The invention relate also the use of the composition of claim 1 for topical use in treating or preventing burning injuries and skin injuries after radiation treatments.
the invention also relate toa method for preparing a composition of claim 1 for suppressing mammalian cancer cell proliferation or growth, said method comprising following steps:
-extracting alcoholic solution of 5-50 wt % of the lignan extract or the mixture of alcoholic lignan extracts with a lower alcohol from one or more of coniferous species selected from genus Picea, Abies, and Pinus; and -admixing betulonic acid or betulinic acid preferably obtained from bark of Betula pendula into the alcoholic solution of lignan extract or the mixture of alcoholic lignan extracts.
The invention relate also a method for preparing a composition for treating melanoma or prostate cancer cells, said method comprising following steps: extracting alcoholic solution of 5-50 wt % of the lignan extract or the mixture of extracts with a lower alcohol from one or more of coniferous species selected from genus Picea, Abies, and Pinus; and admixing betulonic acid or betulinic acid preferably obtained from bark of Betula pendula into the alcoholic solution of lignan extract.
The invention provides also a method for suppressing proliferation or growth of prostate and melanoma cancer cells in vitro, comprising a step of treating said prostate and melanoma cells with a composition, comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid and comprising at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers, as well as a fraction containing various oligolignans.
The invention relate also the use of the composition of claim 1 for topical use in treating or preventing burning injuries and skin injuries after radiation treatments.
the invention also relate toa method for preparing a composition of claim 1 for suppressing mammalian cancer cell proliferation or growth, said method comprising following steps:
-extracting alcoholic solution of 5-50 wt % of the lignan extract or the mixture of alcoholic lignan extracts with a lower alcohol from one or more of coniferous species selected from genus Picea, Abies, and Pinus; and -admixing betulonic acid or betulinic acid preferably obtained from bark of Betula pendula into the alcoholic solution of lignan extract or the mixture of alcoholic lignan extracts.
7 Definitions Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All technical and scientific terms used herein have the same meaning.
Although any materials similar or equivalent to those described herein can also be used in the practice of the present invention, exemplary materials are described for illustrative purposes.
As used herein and in the appended claims, the singular form "a", "and', "the"
include plural referents unless the context clearly dictates otherwise. All technical and scientific terms used herein have the same meaning.
As used herein this disclosure, the terms "weight-percent" and "wt%"
specifically refer to the individual weight of a component or a constituent, taken in relation to the entire total weight of a formulation, unless stated and specified otherwise, in which case, it would be intended to mean the individual weight of the component or the constituent relative to the total volume of the formulation.
As used herein this disclosure, the terms "composition", "dietary composition", or "pharmaceutical composition", are used interchangeably, and hence, they all refer to a composition of matter essentially having a mixture of lignans.
As used herein, the term 'synergistic' or 'synergistically' refer to effect of two or more substances to produce a combined effect greater than the sum of their separate effects.
As used herein, the terms "about" and "approximately' are used interchangeably, and are meant to designate any value which lies preferably within a range of 5%, more preferably within a range of 2%, still more preferably within a range of 1% of its value.
As used herein, the term "pharmaceutically acceptable" is art recognized and refers to compositions, polymers and other materials and/or salts thereof and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reason able benefit/risk ratio.
Although any materials similar or equivalent to those described herein can also be used in the practice of the present invention, exemplary materials are described for illustrative purposes.
As used herein and in the appended claims, the singular form "a", "and', "the"
include plural referents unless the context clearly dictates otherwise. All technical and scientific terms used herein have the same meaning.
As used herein this disclosure, the terms "weight-percent" and "wt%"
specifically refer to the individual weight of a component or a constituent, taken in relation to the entire total weight of a formulation, unless stated and specified otherwise, in which case, it would be intended to mean the individual weight of the component or the constituent relative to the total volume of the formulation.
As used herein this disclosure, the terms "composition", "dietary composition", or "pharmaceutical composition", are used interchangeably, and hence, they all refer to a composition of matter essentially having a mixture of lignans.
As used herein, the term 'synergistic' or 'synergistically' refer to effect of two or more substances to produce a combined effect greater than the sum of their separate effects.
As used herein, the terms "about" and "approximately' are used interchangeably, and are meant to designate any value which lies preferably within a range of 5%, more preferably within a range of 2%, still more preferably within a range of 1% of its value.
As used herein, the term "pharmaceutically acceptable" is art recognized and refers to compositions, polymers and other materials and/or salts thereof and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reason able benefit/risk ratio.
8 As used herein, the terms, "pharmaceutically acceptable agent" and "pharmaceutically acceptable carrier" are used interchangeably, and are meant to have the same meaning, and are art-recognized, and refer to, for example, pharmaceutically acceptable materials, compositions or vehicles, such as a liquid (aqueous or non-aqueous) or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any supplement or composition, or component thereof, from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not injurious to a patient. In certain embodiments, a pharmaceutically acceptable carrier is non pyrogenic.
Some examples of materials which may serve as pharmaceutically acceptable carriers in the context and goal of the embodiments of the invention may include: sugars such as lactose, glucose and sucrose; starches, such as corn starch and potato starch;
cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt, gelatin; talc.; excipients, such as cocoa butter and suppository waxes; oils such as castor oil, olive oil, peanut oil, macadamia nut oil, walnut oil, almond oil, pumpkinseed oil, cottonseed oil, sesame oil, corn oil, soybean oil, avocado oil, palm oil, coconut oil, sunflower oil, safflower oil, flaxseed oil, grapeseed oil, canola oil, low viscosity silicone oil, light mineral oil, or any combination thereof glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol;
esters, such as ethyl oleate and ethyl laurate; agar, buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline;
Ringer's solution; ethyl alcohol; phosphate buffer solutions; gums such as HP-guar;
polymers; and other non-toxic compatible substances employed in pharmaceutical compositions.
It should be understood that operations, and in particular, the method steps may be shown and described as being in a sequence or temporal order, but they are not necessarily limited to being carried out, exactly as claimed, and can therefore be carried out in any particular sequence or order. In other words, as an example, if a method is claimed having at least the steps a), b) and c), a skilled artisan would understand, according to above definition, that the method may equally be performed, for example, by carrying out the method, executing the steps in the order as a), c) and b) etc.
The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to". Terms and phrases used in this application, and
Some examples of materials which may serve as pharmaceutically acceptable carriers in the context and goal of the embodiments of the invention may include: sugars such as lactose, glucose and sucrose; starches, such as corn starch and potato starch;
cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt, gelatin; talc.; excipients, such as cocoa butter and suppository waxes; oils such as castor oil, olive oil, peanut oil, macadamia nut oil, walnut oil, almond oil, pumpkinseed oil, cottonseed oil, sesame oil, corn oil, soybean oil, avocado oil, palm oil, coconut oil, sunflower oil, safflower oil, flaxseed oil, grapeseed oil, canola oil, low viscosity silicone oil, light mineral oil, or any combination thereof glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol;
esters, such as ethyl oleate and ethyl laurate; agar, buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline;
Ringer's solution; ethyl alcohol; phosphate buffer solutions; gums such as HP-guar;
polymers; and other non-toxic compatible substances employed in pharmaceutical compositions.
It should be understood that operations, and in particular, the method steps may be shown and described as being in a sequence or temporal order, but they are not necessarily limited to being carried out, exactly as claimed, and can therefore be carried out in any particular sequence or order. In other words, as an example, if a method is claimed having at least the steps a), b) and c), a skilled artisan would understand, according to above definition, that the method may equally be performed, for example, by carrying out the method, executing the steps in the order as a), c) and b) etc.
The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to". Terms and phrases used in this application, and
9 variations thereof, unless otherwise expressly stated, should be construed as open ended as opposed to limiting. As examples of the foregoing, the term "including"
should be read as meaning "including, without limitation" or the like. The term "example" is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof. Adjectives such as e.g., "conventionaf',"traditional","known" and terms of similar meaning should not be construed as limiting the item described to a given time period, or to an item available as of a given time. But instead, these terms should be read to encompass conventional, traditional, normal, or standard technologies that may be available, known now, or at any time in the future.
Likewise, a group of items linked with the conjunction "and" should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as "and/or" unless expressly stated otherwise. Similarly, a group of items linked with the conjunction "or" should not be read as requiring mutual exclusivity among that group, but rather should also be read as "and/or" unless expressly stated otherwise.
The presence of broadening words and phrases such as "one or more", "at least", "but not limited to", or other like phrases in some instances shall not be read to mean that the narrower case is intended or required in instances, wherein such broadening phrases may be absent.
Throughout this disclosure the concentration of the lignan extract is expressed as molarity (pM). In every case the molarity of the coniferous lignan extract is calculated based on 7-hydroxymatairesinol's molarity. Concentration of betulonic- or betulinic acid is calculated as molarity of the acid in question.
It will be readily understood by one of ordinary skill in the relevant art that the present invention has broad utility and application. Although the present invention has been .. described and illustrated herein with referred to certain embodiments, it will be apparent to those of ordinary skill in the art that other embodiments may perform similar functions and/or achieve like results, and that the described embodiments are for illustrative purposes only.
Thus, it should be understood that various features and aspects of the disclosed of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed invention. Many different embodiments such as variations, adaptations, modifications, and equivalent arrangements are will be implicitly and explicitly disclosed by the embodiments described herein, and thus fall within the scope and spirit of the present invention.
Detailed Description of the Invention 5 Brief description of the drawings The following Figures form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these Figures in combination with the detailed description of the specification embodiments presented herein.
should be read as meaning "including, without limitation" or the like. The term "example" is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof. Adjectives such as e.g., "conventionaf',"traditional","known" and terms of similar meaning should not be construed as limiting the item described to a given time period, or to an item available as of a given time. But instead, these terms should be read to encompass conventional, traditional, normal, or standard technologies that may be available, known now, or at any time in the future.
Likewise, a group of items linked with the conjunction "and" should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as "and/or" unless expressly stated otherwise. Similarly, a group of items linked with the conjunction "or" should not be read as requiring mutual exclusivity among that group, but rather should also be read as "and/or" unless expressly stated otherwise.
The presence of broadening words and phrases such as "one or more", "at least", "but not limited to", or other like phrases in some instances shall not be read to mean that the narrower case is intended or required in instances, wherein such broadening phrases may be absent.
Throughout this disclosure the concentration of the lignan extract is expressed as molarity (pM). In every case the molarity of the coniferous lignan extract is calculated based on 7-hydroxymatairesinol's molarity. Concentration of betulonic- or betulinic acid is calculated as molarity of the acid in question.
It will be readily understood by one of ordinary skill in the relevant art that the present invention has broad utility and application. Although the present invention has been .. described and illustrated herein with referred to certain embodiments, it will be apparent to those of ordinary skill in the art that other embodiments may perform similar functions and/or achieve like results, and that the described embodiments are for illustrative purposes only.
Thus, it should be understood that various features and aspects of the disclosed of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed invention. Many different embodiments such as variations, adaptations, modifications, and equivalent arrangements are will be implicitly and explicitly disclosed by the embodiments described herein, and thus fall within the scope and spirit of the present invention.
Detailed Description of the Invention 5 Brief description of the drawings The following Figures form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these Figures in combination with the detailed description of the specification embodiments presented herein.
10 FIG. 1A shows PC-3 prostate cancer cells 48 hours after treatment with a corresponding 24 pM 1,3-propanediol control.
FIG. 1B shows PC-3 prostate cancer cells treated with 24 pM lignan extract.
FIG. 1C shows untreated control of PC-3 cells containing only growth medium.
All images were taken with a 5x magnification.
FIG. 2A shows PC-3 prostate cancer cells treated with corresponding 24 pM 1,3-propanediol control.
FIG. 2B shows untreated control of PC-3 cells containing only growth medium.
FIG. 2C shows PC-3 prostate cancer cells 48 hours after treatment with 24 pM
lignan extract of this disclosure. All images were taken with a 20x magnification.
FIG. 3A shows live-cell imaging of PC-3 prostate cancer cell proliferation during a 48-hour treatment with different concentrations of a lignan extract of this disclosure or control exposure. Y-axis represents the confluency of cells per well (20000 cells at seeding), meaning the percent of well surface covered in adherent cells. Each point on the graph is the mean confluency of triplicate samples on a 24-well plate. PC-3 cells were either treated with 24 pM, 36 pM, or 60 pM 1,3-propanediol as solvent control, or with 24 pM, 36 pM or 60 pM lignan extract, or with an untreated control comprising only the growth medium.
FIG. 1B shows PC-3 prostate cancer cells treated with 24 pM lignan extract.
FIG. 1C shows untreated control of PC-3 cells containing only growth medium.
All images were taken with a 5x magnification.
FIG. 2A shows PC-3 prostate cancer cells treated with corresponding 24 pM 1,3-propanediol control.
FIG. 2B shows untreated control of PC-3 cells containing only growth medium.
FIG. 2C shows PC-3 prostate cancer cells 48 hours after treatment with 24 pM
lignan extract of this disclosure. All images were taken with a 20x magnification.
FIG. 3A shows live-cell imaging of PC-3 prostate cancer cell proliferation during a 48-hour treatment with different concentrations of a lignan extract of this disclosure or control exposure. Y-axis represents the confluency of cells per well (20000 cells at seeding), meaning the percent of well surface covered in adherent cells. Each point on the graph is the mean confluency of triplicate samples on a 24-well plate. PC-3 cells were either treated with 24 pM, 36 pM, or 60 pM 1,3-propanediol as solvent control, or with 24 pM, 36 pM or 60 pM lignan extract, or with an untreated control comprising only the growth medium.
11 FIG. 3B shows selectively the same data as Fig. 3A. Now only treatment with the lignan extracts (24 pM, 36 pM, and 60 pM) and the untreated controls are shown.
Statistical analysis using one-way ANOVA and Dunette's multiple comparisons test done with GraphPad Prism 6 software of the data at the exposure time of 48 hours indicated significant differences between untreated and 60 M extract treated PC-3 cells (P<0.05).
FIG. 3C shows cell viability of serum-starved PC-3 cells measured after 24-hour treatment with different concentrations of lignan extract from Picea abies. IC50-value in these treatment conditions was measured to equal 20.02 M using GraphPad Prism 6 software.
FIG. 4A shows SK-Mel-5 melanoma cancer cells 48 hours after treatment with 24 pM
corresponding 1,3-propanediol control.
FIG. 4B shows SK-Mel-5 melanoma cancer cells treated with 24 pM lignan extract.
FIG. 4C shows a control of SK-Mel-5 cells in growth medium. SK-Mel-5 melanoma cancer cells proliferate at a high rate both in the lignan extract-treated sample and in controls.
No significant effect was observed with the lignan exposure. All images were taken with a 5x magnification.
FIG. 5A shows SK-Mel-5 melanoma cancer cells 48 hours after treatment with 24 pM
corresponding 1,3-propanediol.
FIG. 5B shows SK-Mel-5 melanoma cancer cells treated with 60 pM lignan extract.
FIG. 5C shows untreated SK-Mel-5 cells in growth medium. SK-Mel-5 melanoma cancer cells proliferate at a high rate both in the treated sample and when treated with the controls. No significant effect was observed with the lignan exposure. All images were taken with a 20x magnification.
FIG. 6A shows live-cell imaging of WM-266-4 melanoma cancer cell proliferation during a 48-hour treatment with different concentrations of the lignan extract or control exposure.
Y-axis represents the confluency of cells per well (30000 cells at seeding), meaning the percent of well surface covered adherent cells. Each point on the graph is the mean of triplicate samples on a 24-well plate. WM-266-4 melanoma cancer cells were either treated with 24 pM, 36 pM, or 60 pM propanediol control, or 24 pM, 36 pM or 60 pM lignan extract, or with an untreated control comprising only the growth medium.
Statistical analysis using one-way ANOVA and Dunette's multiple comparisons test done with GraphPad Prism 6 software of the data at the exposure time of 48 hours indicated significant differences between untreated and 60 M extract treated PC-3 cells (P<0.05).
FIG. 3C shows cell viability of serum-starved PC-3 cells measured after 24-hour treatment with different concentrations of lignan extract from Picea abies. IC50-value in these treatment conditions was measured to equal 20.02 M using GraphPad Prism 6 software.
FIG. 4A shows SK-Mel-5 melanoma cancer cells 48 hours after treatment with 24 pM
corresponding 1,3-propanediol control.
FIG. 4B shows SK-Mel-5 melanoma cancer cells treated with 24 pM lignan extract.
FIG. 4C shows a control of SK-Mel-5 cells in growth medium. SK-Mel-5 melanoma cancer cells proliferate at a high rate both in the lignan extract-treated sample and in controls.
No significant effect was observed with the lignan exposure. All images were taken with a 5x magnification.
FIG. 5A shows SK-Mel-5 melanoma cancer cells 48 hours after treatment with 24 pM
corresponding 1,3-propanediol.
FIG. 5B shows SK-Mel-5 melanoma cancer cells treated with 60 pM lignan extract.
FIG. 5C shows untreated SK-Mel-5 cells in growth medium. SK-Mel-5 melanoma cancer cells proliferate at a high rate both in the treated sample and when treated with the controls. No significant effect was observed with the lignan exposure. All images were taken with a 20x magnification.
FIG. 6A shows live-cell imaging of WM-266-4 melanoma cancer cell proliferation during a 48-hour treatment with different concentrations of the lignan extract or control exposure.
Y-axis represents the confluency of cells per well (30000 cells at seeding), meaning the percent of well surface covered adherent cells. Each point on the graph is the mean of triplicate samples on a 24-well plate. WM-266-4 melanoma cancer cells were either treated with 24 pM, 36 pM, or 60 pM propanediol control, or 24 pM, 36 pM or 60 pM lignan extract, or with an untreated control comprising only the growth medium.
12 FIG. 6B shows selectively the same data as Fig. 6A. Now only treatment with the lignan extracts (24 pM, 36 pM, and 60 pM) and the untreated controls are shown.
Statistical analysis using one-way ANOVA and Dunette's multiple comparisons test done with GraphPad Prism 6 software of the data at the exposure time of 48 hours indicated significant differences between untreated and 60 M extract treated WM-266-4 cells (P<0.05).
FIGs 7A-7D illustrate percentual proportion of PC-3 cells in various stages of the cell cycle after a 24-hour treatment with lignan extracts or controls ( SEM). Statistical analysis was carried out by one-way ANOVA followed by Tukey's multiple comparison test using GraphPad Prism 6 software. ' and *' represent a significance value where P <
0.001 and P < 0.0001, respectively.
FIG. 7A shows the percentual proportion of PC-3 cells in GO/G1-phase after a 24-hour treatment with growth medium only (control), with 24 pM lignan extract, and with 60 pM
lignan extract.
Fig. 7B shows the percentual proportion of PC-3 cells in S-phase after a 24-hour treatment with growth medium only (control), with 24 pM lignan extract, and with 60 pM
lignan extract.
FIG. 7C percentual proportion of PC-3 cells in G2/M-phase after a 24-hour treatment with growth medium only (control), with 24 pM lignan extract, and with 60 pM lignan extract.
FIG. 7D represents flow cytometry results from one individual example experiment with propidium iodide stained PC-3 cells treated for 24 hours with growth medium only (control;
the lowermost curve); cells treated with 24 pM extract for 24 hours (middle curve) and with 60 pM extract for 24 hours (uppermost curve). Significant differences in the proportion of cells in GO/G1-phase and G2/M-phase can be observed when comparing the curves, indicating that the treated cells are accumulating in GO/G1-phase of the cell cycle.
FIG. 8A shows live-cell imaging of normal human dermal fibroblast (HDF) cell proliferation during 48h treatment with betulinic acid (BA). Results are mean values from three independent experiments ( SEM).
Statistical analysis using one-way ANOVA and Dunette's multiple comparisons test done with GraphPad Prism 6 software of the data at the exposure time of 48 hours indicated significant differences between untreated and 60 M extract treated WM-266-4 cells (P<0.05).
FIGs 7A-7D illustrate percentual proportion of PC-3 cells in various stages of the cell cycle after a 24-hour treatment with lignan extracts or controls ( SEM). Statistical analysis was carried out by one-way ANOVA followed by Tukey's multiple comparison test using GraphPad Prism 6 software. ' and *' represent a significance value where P <
0.001 and P < 0.0001, respectively.
FIG. 7A shows the percentual proportion of PC-3 cells in GO/G1-phase after a 24-hour treatment with growth medium only (control), with 24 pM lignan extract, and with 60 pM
lignan extract.
Fig. 7B shows the percentual proportion of PC-3 cells in S-phase after a 24-hour treatment with growth medium only (control), with 24 pM lignan extract, and with 60 pM
lignan extract.
FIG. 7C percentual proportion of PC-3 cells in G2/M-phase after a 24-hour treatment with growth medium only (control), with 24 pM lignan extract, and with 60 pM lignan extract.
FIG. 7D represents flow cytometry results from one individual example experiment with propidium iodide stained PC-3 cells treated for 24 hours with growth medium only (control;
the lowermost curve); cells treated with 24 pM extract for 24 hours (middle curve) and with 60 pM extract for 24 hours (uppermost curve). Significant differences in the proportion of cells in GO/G1-phase and G2/M-phase can be observed when comparing the curves, indicating that the treated cells are accumulating in GO/G1-phase of the cell cycle.
FIG. 8A shows live-cell imaging of normal human dermal fibroblast (HDF) cell proliferation during 48h treatment with betulinic acid (BA). Results are mean values from three independent experiments ( SEM).
13 FIG. 8B shows live-cell imaging of normal human dermal fibroblast (HDF) cell proliferation during 48h treatment with betulonic acid (BOA). Results are mean values from three independent experiments ( SEM).
FIG. 9A shows live-cell imaging of metastatic prostate cancer (PC-3) cell proliferation during 48h treatment with betulinic acid (BA) ( SE).
FIG: 9B shows live-cell imaging of metastatic melanoma (WM-266-4) cell proliferation during 48h treatment with betulonic acid (BOA) ( SE).
FIG. 9C shows live-cell imaging of metastatic prostate cancer (PC-3) cell proliferation during 48h treatment with betulonic acid ( SE).
FIG. 10 A shows cytotoxicity assay of betulinic acid (BA) on metastatic melanoma (WM-266-4) cells after 48h treatment ( SEM). Results are mean values from three independent experiments.
FIG. 10B shows cytotoxicity assay of betulinic acid (BA) on metastatic prostate cancer (PC-3) cells after 48h treatment ( SEM). Results are mean values from three independent experiments.
FIG: 11A shows cytotoxicity assay of betulonic acid (BOA) on metastatic prostate cancer (PC-3) cells after 48h treatment ( SEM). Results are mean values from three independent experiments.
FIG. 11 B shows cytotoxicity assay of betulonic acid (BOA) on metastatic melanoma (WM-266-4) cells after 48h treatment ( SEM). Results are mean values from three independent experiments.
FIG. 12 A. shows live-cell imaging of cell proliferation of PC-3 cells treated with P. abies knotwood extract with or without betulonic acid (BOA) for 48 hours. Values represent two independent experiments ( SEM).
FIG: 12 B. shows live-cell imaging of cell proliferation of PC-3 cells treated with P. abies knotwood extract with or without betulinic acid (BA) for 48 hours. Values represent two independent experiments ( SEM).
FIG. 9A shows live-cell imaging of metastatic prostate cancer (PC-3) cell proliferation during 48h treatment with betulinic acid (BA) ( SE).
FIG: 9B shows live-cell imaging of metastatic melanoma (WM-266-4) cell proliferation during 48h treatment with betulonic acid (BOA) ( SE).
FIG. 9C shows live-cell imaging of metastatic prostate cancer (PC-3) cell proliferation during 48h treatment with betulonic acid ( SE).
FIG. 10 A shows cytotoxicity assay of betulinic acid (BA) on metastatic melanoma (WM-266-4) cells after 48h treatment ( SEM). Results are mean values from three independent experiments.
FIG. 10B shows cytotoxicity assay of betulinic acid (BA) on metastatic prostate cancer (PC-3) cells after 48h treatment ( SEM). Results are mean values from three independent experiments.
FIG: 11A shows cytotoxicity assay of betulonic acid (BOA) on metastatic prostate cancer (PC-3) cells after 48h treatment ( SEM). Results are mean values from three independent experiments.
FIG. 11 B shows cytotoxicity assay of betulonic acid (BOA) on metastatic melanoma (WM-266-4) cells after 48h treatment ( SEM). Results are mean values from three independent experiments.
FIG. 12 A. shows live-cell imaging of cell proliferation of PC-3 cells treated with P. abies knotwood extract with or without betulonic acid (BOA) for 48 hours. Values represent two independent experiments ( SEM).
FIG: 12 B. shows live-cell imaging of cell proliferation of PC-3 cells treated with P. abies knotwood extract with or without betulinic acid (BA) for 48 hours. Values represent two independent experiments ( SEM).
14 FIG 12 C. shows live-cell imaging of cell proliferation of WM-266-4 cells treated with P.
abies knotwood extract with or without betulonic acid (BOA) for 48 hours.
FIG: 12 B. shows live-cell imaging of cell proliferation of WM-266-4 cells treated with P.
abies knotwood extract with or without betulinic acid (BA) for 48 hours.
Preparation of the composition The composition of the present invention is based on the fact that the phenolic compounds, such as lignans, tannins and flavonoids contained in the wood material, are extracted from the wood with an extraction medium, which as such, is suitable for various food products. Extraction medium may be an extraction solution or subcritical or supercritical extraction fluid, such as CO2. In the previous practice of the art, lignans, tannins and flavonoids have been purified before using them in food industry.
Different from the previous practice exploited, the particular embodiments of the present invention, is based on the fact, that the raw extraction solution or extraction fluid is not purified before use. The raw extraction solution, i.e. wood extract or raw extraction fluid-wood extract is recovered from the wood material, such as wood chips or chipped wood pulp of the chemical pulp industry, which contain(s) lignans and/or flavonoids and/or tannins as active ingredients and are/is then subsequently used for as a dietary supplement, as a composition for further preparing medicaments or natural treatments, or alternatively as an additive in various food products, or semi-finished food products.
In a case, this composition according to the particular embodiments of the present invention being a solution composed of liquid -wood extract, the relative amounts of the active chemical compositions in the lignan mixture may be modified for better suiting in a designed use. This can be obtained, for example by a fractionating extracting procedure.
The solvent to be used as an extraction solution may be simply selected on the basis of its suitability to further uses. This provides the advantage that the isolation of the raw extraction solution ¨wood extract or raw extraction fluid-wood extract from the wood material is simple and requires a considerably smaller number of process stages than before.
Preferably the lignan mixture used in the products and compositions according to the particular embodiments of the present invention is obtained by extracting or grinding wood bark and/or knot wood from coniferous species from the genus Picea and/or Abies.
According to certain embodiments also species from the genus Pinus may be used.
According to certain embodiments also species from the genus Betula may be used.
An extract from Picea abies (Norwegian spruce tree) is one preferable embodiment and 5 the lignan extract obtained from knot wood of Norwegian spruce tree has the following proportions of lignans: 7-hydroxymatairesinol 70-80 wt%; conidendrin 3-8 wt%;
lariciresinol 1-4 wt%; liovil 2-5 wt%; secoisolariciresinol 3-7 wt%, other lignans 0-3 wt%.
Usually, this lignan mixture may also contain oligolignans and the fraction of 'other lignans' contains various oligolignans. Into this lignan mixture betulonic or betulinic acid, 10 or both of them may also be added. Betulonic or betulinic acid may originate from lignan extract from Betula species.
Depending on the source of wood material, the extract may also contain other wood lignans, such as but not limited to, pinoresinol, nortrachelogenin, matairesinol and juvabiones.
abies knotwood extract with or without betulonic acid (BOA) for 48 hours.
FIG: 12 B. shows live-cell imaging of cell proliferation of WM-266-4 cells treated with P.
abies knotwood extract with or without betulinic acid (BA) for 48 hours.
Preparation of the composition The composition of the present invention is based on the fact that the phenolic compounds, such as lignans, tannins and flavonoids contained in the wood material, are extracted from the wood with an extraction medium, which as such, is suitable for various food products. Extraction medium may be an extraction solution or subcritical or supercritical extraction fluid, such as CO2. In the previous practice of the art, lignans, tannins and flavonoids have been purified before using them in food industry.
Different from the previous practice exploited, the particular embodiments of the present invention, is based on the fact, that the raw extraction solution or extraction fluid is not purified before use. The raw extraction solution, i.e. wood extract or raw extraction fluid-wood extract is recovered from the wood material, such as wood chips or chipped wood pulp of the chemical pulp industry, which contain(s) lignans and/or flavonoids and/or tannins as active ingredients and are/is then subsequently used for as a dietary supplement, as a composition for further preparing medicaments or natural treatments, or alternatively as an additive in various food products, or semi-finished food products.
In a case, this composition according to the particular embodiments of the present invention being a solution composed of liquid -wood extract, the relative amounts of the active chemical compositions in the lignan mixture may be modified for better suiting in a designed use. This can be obtained, for example by a fractionating extracting procedure.
The solvent to be used as an extraction solution may be simply selected on the basis of its suitability to further uses. This provides the advantage that the isolation of the raw extraction solution ¨wood extract or raw extraction fluid-wood extract from the wood material is simple and requires a considerably smaller number of process stages than before.
Preferably the lignan mixture used in the products and compositions according to the particular embodiments of the present invention is obtained by extracting or grinding wood bark and/or knot wood from coniferous species from the genus Picea and/or Abies.
According to certain embodiments also species from the genus Pinus may be used.
According to certain embodiments also species from the genus Betula may be used.
An extract from Picea abies (Norwegian spruce tree) is one preferable embodiment and 5 the lignan extract obtained from knot wood of Norwegian spruce tree has the following proportions of lignans: 7-hydroxymatairesinol 70-80 wt%; conidendrin 3-8 wt%;
lariciresinol 1-4 wt%; liovil 2-5 wt%; secoisolariciresinol 3-7 wt%, other lignans 0-3 wt%.
Usually, this lignan mixture may also contain oligolignans and the fraction of 'other lignans' contains various oligolignans. Into this lignan mixture betulonic or betulinic acid, 10 or both of them may also be added. Betulonic or betulinic acid may originate from lignan extract from Betula species.
Depending on the source of wood material, the extract may also contain other wood lignans, such as but not limited to, pinoresinol, nortrachelogenin, matairesinol and juvabiones.
15 In some particular embodiments, the raw extraction solution -wood extract may preferably be from a single tree species, especially from spruce tree (Picea sp). In some particular embodiments, the tree may be the Norwegian spruce tree (Picea abies L). In other particular embodiments, a mixture that originates from two or more tree species may equally, and advantageously be applied, exemplary beneficial mixture originating from a spruce (Picea sp.) and/or fir (Abies sp.) and a pine (Pinus sp.) or from a conifer and a birch (Betula sp.). According to certain embodiments a mixture is made of multiple wood extracts. According to certain embodiments one extract is received from a mixture of wood chips of more than one species. According to a preferred embodiment the extract is received from a mixture of wood chips of two species; according to a preferred embodiment the species are Picea abies and Pinus sp. (e.g. Pinus sylvestris L.).
According to one preferred embodiment the species are Picea abies and Betula sp.
According to one preferred embodiment the species are Pinus sp. and Betula sp.
According to certain embodiments the mixture is obtained from more than two species;
according to certain embodiments the mixture is obtained from Picea abies, Pinus sp. and Betula sp. In certain preferred embodiments, the wood may originate from trees belonging to the genus Picea or the genus Abies. According to certain embodiments the mixture is
According to one preferred embodiment the species are Picea abies and Betula sp.
According to one preferred embodiment the species are Pinus sp. and Betula sp.
According to certain embodiments the mixture is obtained from more than two species;
according to certain embodiments the mixture is obtained from Picea abies, Pinus sp. and Betula sp. In certain preferred embodiments, the wood may originate from trees belonging to the genus Picea or the genus Abies. According to certain embodiments the mixture is
16 prepared of lignan extracts from Picea species and from Abies species.
According to certain embodiments the mixture is prepared from lignan extracts from Picea sp. and/or Abies sp. and of Pinus sp. and/or Betula sp. In certain other particular embodiments, the wood extract may originate specifically from Picea sp., Tsuga sp. (hemlock) or Acacia sp.
In still other particular embodiments, the wood extract may additionally originate from bark of Betula sp., preferably Betula pendula (European white birch).
The types and amounts of mixture of lignan extracts obtained from different wood species vary considerably. By adding, and thereby combining, lignan extracts from various wood species, or plants, one might modify the altogether effect synergistically of the lignan mixture (i.e. active ingredient). As is shown here, adding betulinic or betulonic acid to lignan extract from P. abies has a clearly synergistic effect in vitro on prevention of cell proliferation of metastatic prostate cancer or melanoma cells.
For extraction of knot wood and/or bark with an extraction solution, for obtaining an alcohol-wood extract or an alcohol-water-wood extract, various alcohol-based solvents, such as but not limited to, butylene glycol, butylene glycol + monoalcohol, glycerol or glycerol + alcohol may be used. These alcohol-based solvents are either physiologically acceptable or/and edible.
The extraction solution may preferably contain a lower monovalent or bivalent alkyl alcohol or a mixture of a lower monovalent and a bivalent alkyl alcohol and/or glycerol, or a mixture of a lower (monovalent) alkyl alcohol and a bivalent or a trivalent lower alkyl alcohol. The monovalent alcohol may advantageously be ethanol, propanol, butanol, heptanol, octanol or decanol. The monoalcohol may especially and preferably be ethanol.
The bivalent alkyl alcohol may preferably be a lower alkylene glycol, which may preferably be selected from the group consisting of ethylene glycol, propylene glycol, butylene glycol, pentylene glycol, and dipropylene glycol. Butylene glycol is an especially preferable solvent, as the lignan mixture according to particular embodiments of the present the invention dissolves therein in amounts of over 10% and it is physiologically tolerable.
Solutions of ethanol and bivalent alcohols are preferable for dissolving and also for extracting the lignan mixtures according to the particular embodiments of the invention.
Bivalent alcohol may especially and preferably be selected from the group composing of
According to certain embodiments the mixture is prepared from lignan extracts from Picea sp. and/or Abies sp. and of Pinus sp. and/or Betula sp. In certain other particular embodiments, the wood extract may originate specifically from Picea sp., Tsuga sp. (hemlock) or Acacia sp.
In still other particular embodiments, the wood extract may additionally originate from bark of Betula sp., preferably Betula pendula (European white birch).
The types and amounts of mixture of lignan extracts obtained from different wood species vary considerably. By adding, and thereby combining, lignan extracts from various wood species, or plants, one might modify the altogether effect synergistically of the lignan mixture (i.e. active ingredient). As is shown here, adding betulinic or betulonic acid to lignan extract from P. abies has a clearly synergistic effect in vitro on prevention of cell proliferation of metastatic prostate cancer or melanoma cells.
For extraction of knot wood and/or bark with an extraction solution, for obtaining an alcohol-wood extract or an alcohol-water-wood extract, various alcohol-based solvents, such as but not limited to, butylene glycol, butylene glycol + monoalcohol, glycerol or glycerol + alcohol may be used. These alcohol-based solvents are either physiologically acceptable or/and edible.
The extraction solution may preferably contain a lower monovalent or bivalent alkyl alcohol or a mixture of a lower monovalent and a bivalent alkyl alcohol and/or glycerol, or a mixture of a lower (monovalent) alkyl alcohol and a bivalent or a trivalent lower alkyl alcohol. The monovalent alcohol may advantageously be ethanol, propanol, butanol, heptanol, octanol or decanol. The monoalcohol may especially and preferably be ethanol.
The bivalent alkyl alcohol may preferably be a lower alkylene glycol, which may preferably be selected from the group consisting of ethylene glycol, propylene glycol, butylene glycol, pentylene glycol, and dipropylene glycol. Butylene glycol is an especially preferable solvent, as the lignan mixture according to particular embodiments of the present the invention dissolves therein in amounts of over 10% and it is physiologically tolerable.
Solutions of ethanol and bivalent alcohols are preferable for dissolving and also for extracting the lignan mixtures according to the particular embodiments of the invention.
Bivalent alcohol may especially and preferably be selected from the group composing of
17 ethylene glycol, propylene glycol, butylene glycol, pentylene glycol, and dipropylene glycol.
Suitable trivalent alcohol solvents may, for example, be glycerols.
The mixture of the lower alkyl alcohol and glycerol or alkyl glycol is a preferable solvent medium, as the need to further process the raw extracts (= solvent + active ingredient mixture) or raw extract concentrates based on extraction solutions containing such alcohols is as small as possible, when preparing different food additives or food grade compositions.
The alcohol or water-alcohol based raw alcohol-wood extracts or alcohol-wood extracts are well-suited to the manufacture of food-grade components or to be used as such.
These food grade components include, without limiting to them, emulsions, dispersions, oils, sweeteners.
The present lignan mixture of the particular embodiments of the present invention may also be mixed with carrier or extraction solvents, which are appropriate food additives.
The lignan mixture can be either powder or alcohol- water-wood extract or simply alcohol-wood extract. These carrier or extraction solvents may include the following, but not limited to: acetone, benzyl alcohol, 1,3-butylene glycol, carbon dioxide, castor oil, citric acid esters of mono-and diglycerides, ethyl acetate, ethanol, glycerol (glycerin), glyceryl diacetate, glyceryl triacetate, glyceryl tributyrate, hexane, isopropanol alcohol, methyl alcohol, methyl ethyl ketone(2-butanone), methylene chloride, mono- and diglycerides, monoglyceride citrate, 2-nitropropane, 1,2-propylene glycol (1,2-propanediol), propylene glycol monoesters and diesters of fat-forming fatty acids, triethyl citrate.
Certain particular embodiments of the present invention are related to compositions, and use of such compositions in methods for suppressing proliferation or growth of cancer cells in vitro or in vivo, of at least of prostate and melanoma cancer cells, but also brain cancer cells, colon cancer cells, and breast cancer cells, where the compositions are lignan extracts comprising at least 7-hydroxymatairesinol, conidendrin ;
lariciresinol; liovil;
and secoisolariciresinol. Certain particular embodiments of the present invention also comprise a fraction containing various oligolignans. Certain particular embodiments comprise adding betulonic or betulinic acid in low concentrations to the compositions of
Suitable trivalent alcohol solvents may, for example, be glycerols.
The mixture of the lower alkyl alcohol and glycerol or alkyl glycol is a preferable solvent medium, as the need to further process the raw extracts (= solvent + active ingredient mixture) or raw extract concentrates based on extraction solutions containing such alcohols is as small as possible, when preparing different food additives or food grade compositions.
The alcohol or water-alcohol based raw alcohol-wood extracts or alcohol-wood extracts are well-suited to the manufacture of food-grade components or to be used as such.
These food grade components include, without limiting to them, emulsions, dispersions, oils, sweeteners.
The present lignan mixture of the particular embodiments of the present invention may also be mixed with carrier or extraction solvents, which are appropriate food additives.
The lignan mixture can be either powder or alcohol- water-wood extract or simply alcohol-wood extract. These carrier or extraction solvents may include the following, but not limited to: acetone, benzyl alcohol, 1,3-butylene glycol, carbon dioxide, castor oil, citric acid esters of mono-and diglycerides, ethyl acetate, ethanol, glycerol (glycerin), glyceryl diacetate, glyceryl triacetate, glyceryl tributyrate, hexane, isopropanol alcohol, methyl alcohol, methyl ethyl ketone(2-butanone), methylene chloride, mono- and diglycerides, monoglyceride citrate, 2-nitropropane, 1,2-propylene glycol (1,2-propanediol), propylene glycol monoesters and diesters of fat-forming fatty acids, triethyl citrate.
Certain particular embodiments of the present invention are related to compositions, and use of such compositions in methods for suppressing proliferation or growth of cancer cells in vitro or in vivo, of at least of prostate and melanoma cancer cells, but also brain cancer cells, colon cancer cells, and breast cancer cells, where the compositions are lignan extracts comprising at least 7-hydroxymatairesinol, conidendrin ;
lariciresinol; liovil;
and secoisolariciresinol. Certain particular embodiments of the present invention also comprise a fraction containing various oligolignans. Certain particular embodiments comprise adding betulonic or betulinic acid in low concentrations to the compositions of
18 lignan extracts comprising at least 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil, secoisolariciresinol and optionally also various oligolignans.
Certain particular embodiment of the present invention are related to compositions, and use of such compositions in methods for suppressing proliferation or growth of cancer cells in vitro or in vivo, of at least of prostate and melanoma cancer cells but also brain cancer cells, colon cancer, and breast cancer cells, where the compositions are lignan extracts comprising 7-hydroxymatairesinol 70-80 wt%; conidendrin 3-8 wt%;
lariciresinol 1-4 wt%; liovil 2-5 wt%; secoisolariciresinol 3-7 wt%, other lignans 0-3 wt%, and optionally betulonic or betulinic acid.
Certain particular embodiments of the present invention are related to compositions, and use of such compositions in methods for suppressing proliferation or growth of cancer cells in vitro or in vivo, of at least of prostate and melanoma cancer cells but also brain cancer cells, colon cancer, and breast cancer cells, where the compositions are lignan extracts including additionally one or more lignan(s) at a range of 0-10 wt%
selected from the group consisting of: pinoresinol, nortrachelogenin, matairesinol, juvabiones, or their geometric isomers or stereoisomers thereof and oligolignans. Into the compositions may further be added betulonic and/ or betulinic acid to achieve synergistic effects in cell proliferation.
Certain particular embodiments of the present invention are related to compositions, and use of such composition in methods for suppressing proliferation or growth of cancer cells in vitro or in vivo, of at least of prostate and melanoma cancer cells but also brain cancer cells, colon cancer, and breast cancer cells, where the compositions are lignan extracts and the composition further include stilbenes or triterpens selected from the group consisting of betulin, betulonic acid, betulinic acid, betuloinic acid, resveratrol, their geometric isomers and stereoisomers thereof and oligolignans. Into the compositions may further be added betulonic and/ or betulinic acid to achieve synergistic effects in cell proliferation.
Certain particular embodiments of the present invention are related to compositions and use of such compositions in methods for suppressing proliferation or growth of cancer .. cells in vitro or in vivo, of at least of prostate and melanoma cancer cells but also brain cancer cells, colon cancer, and breast cancer cells, where the compositions are lignan
Certain particular embodiment of the present invention are related to compositions, and use of such compositions in methods for suppressing proliferation or growth of cancer cells in vitro or in vivo, of at least of prostate and melanoma cancer cells but also brain cancer cells, colon cancer, and breast cancer cells, where the compositions are lignan extracts comprising 7-hydroxymatairesinol 70-80 wt%; conidendrin 3-8 wt%;
lariciresinol 1-4 wt%; liovil 2-5 wt%; secoisolariciresinol 3-7 wt%, other lignans 0-3 wt%, and optionally betulonic or betulinic acid.
Certain particular embodiments of the present invention are related to compositions, and use of such compositions in methods for suppressing proliferation or growth of cancer cells in vitro or in vivo, of at least of prostate and melanoma cancer cells but also brain cancer cells, colon cancer, and breast cancer cells, where the compositions are lignan extracts including additionally one or more lignan(s) at a range of 0-10 wt%
selected from the group consisting of: pinoresinol, nortrachelogenin, matairesinol, juvabiones, or their geometric isomers or stereoisomers thereof and oligolignans. Into the compositions may further be added betulonic and/ or betulinic acid to achieve synergistic effects in cell proliferation.
Certain particular embodiments of the present invention are related to compositions, and use of such composition in methods for suppressing proliferation or growth of cancer cells in vitro or in vivo, of at least of prostate and melanoma cancer cells but also brain cancer cells, colon cancer, and breast cancer cells, where the compositions are lignan extracts and the composition further include stilbenes or triterpens selected from the group consisting of betulin, betulonic acid, betulinic acid, betuloinic acid, resveratrol, their geometric isomers and stereoisomers thereof and oligolignans. Into the compositions may further be added betulonic and/ or betulinic acid to achieve synergistic effects in cell proliferation.
Certain particular embodiments of the present invention are related to compositions and use of such compositions in methods for suppressing proliferation or growth of cancer .. cells in vitro or in vivo, of at least of prostate and melanoma cancer cells but also brain cancer cells, colon cancer, and breast cancer cells, where the compositions are lignan
19 extracts from coniferous species such as Picea sp. or Pinus sp., with optionally added betulonic or betulinic acids preferably extracted from Betula sp. and the composition further includes comprises vitamins or micronutrients.
Certain particular embodiments of the present invention are related to a method for preparing a composition and use of a lignan extract or a mixture of lignan extracts for suppressing cancer cell growth and/or proliferation, in vitro or in vivo, or for preparation of treatments to suppress cancer cell growth and/or proliferation, where the composition includes at a range of 1-50 wt%, preferably 5-50 wt% of a lignan mixture including at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil, secoisolariciresinol or their geometric isomers or stereoisomers thereof as well as a fraction containing various oligolignans and optionally added betulonic or betulinic acids, which method, includes at least the following steps:
a) extracting the mixture of lignans from a wood bark and/or knot wood from one or more coniferous species selected from genus Picea, Abies, and Pinus, with an extraction solution selected from the group consisting of an alcohol and an alcohol-water mixture;
b) obtaining an alcohol-wood lignan mixture or an alcohol-water-wood lignan mixture;
c) optionally adding betulonic or betulinic acid preferably extracted from Betula sp. and added as an alcohol mixture, and d) adding a physiologically and pharmaceutically acceptable carrier agent to the mixture.
According to certain embodiment the composition for use in prevention of cancer cell growth and/or proliferation comprises 1-50 wt% of a lignan mixture of the total composition. More preferably, the amount of the lignan extract is about 5-50 wt% of the total composition.
According to certain embodiment the composition has 10-100 pM betulinic acid or betulonic acid. More preferably the composition has 10-60 pM betulinic acid or betulonic acid. Most preferably the composition has 20-40 pM betulinic acid or betulonic acid. A
preferred concentration is approximately 30 pM betulonic or betulinic acid in the extract.
According to certain embodiment the composition comprising 1-50 wt% of a lignan extract with optional addition of betulonic or betulinic acid can be used for preventing cancer cell growth and/or proliferation in relatively small quantities. According to certain embodiments a daily dosage of the extract amounts to 20 to 250 mg, more preferably to 50 to 200 mg and most preferably to 100-200 mg of 7- hydroxymatairesinol along with other lignans selected from the group consisting of conidendrin, lariciresinol, liovil and secoisolariciresinol and oligolignans and optionally betulonic or betulinic acid in a 5 concentration of about 30 pM.
According to certain embodiment the daily dosage of the extract is such that it contains 100-200 mg of 7-hydroxymatairesinol, 4-8 mg each of the following lignans scoisolariciresinol, condendrin, liovil, lariciresinol, and 4-20 mg other lignans including oligolignans.
10 The embodiments of the present invention relate to the use of a composition including at a range of 1-50 wt%, preferably at a range of 5-50 wt% of a lignan mixture including at least following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers thereof along with oligolingnans and optionally betulonic or betulinic acid for lowering, suppressing, and 15 .. thereby inhibiting, in vitro, the proliferation and growth of mammalian cancer cells. As used herein this disclosure, the percent ranges given for the lignan mixture specifically refers to percent by weight of the total composition.
To be more exact, the particular embodiments of the present invention relate to i) a composition, ii) methods of preparing the composition, and iii) methods of using the
Certain particular embodiments of the present invention are related to a method for preparing a composition and use of a lignan extract or a mixture of lignan extracts for suppressing cancer cell growth and/or proliferation, in vitro or in vivo, or for preparation of treatments to suppress cancer cell growth and/or proliferation, where the composition includes at a range of 1-50 wt%, preferably 5-50 wt% of a lignan mixture including at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil, secoisolariciresinol or their geometric isomers or stereoisomers thereof as well as a fraction containing various oligolignans and optionally added betulonic or betulinic acids, which method, includes at least the following steps:
a) extracting the mixture of lignans from a wood bark and/or knot wood from one or more coniferous species selected from genus Picea, Abies, and Pinus, with an extraction solution selected from the group consisting of an alcohol and an alcohol-water mixture;
b) obtaining an alcohol-wood lignan mixture or an alcohol-water-wood lignan mixture;
c) optionally adding betulonic or betulinic acid preferably extracted from Betula sp. and added as an alcohol mixture, and d) adding a physiologically and pharmaceutically acceptable carrier agent to the mixture.
According to certain embodiment the composition for use in prevention of cancer cell growth and/or proliferation comprises 1-50 wt% of a lignan mixture of the total composition. More preferably, the amount of the lignan extract is about 5-50 wt% of the total composition.
According to certain embodiment the composition has 10-100 pM betulinic acid or betulonic acid. More preferably the composition has 10-60 pM betulinic acid or betulonic acid. Most preferably the composition has 20-40 pM betulinic acid or betulonic acid. A
preferred concentration is approximately 30 pM betulonic or betulinic acid in the extract.
According to certain embodiment the composition comprising 1-50 wt% of a lignan extract with optional addition of betulonic or betulinic acid can be used for preventing cancer cell growth and/or proliferation in relatively small quantities. According to certain embodiments a daily dosage of the extract amounts to 20 to 250 mg, more preferably to 50 to 200 mg and most preferably to 100-200 mg of 7- hydroxymatairesinol along with other lignans selected from the group consisting of conidendrin, lariciresinol, liovil and secoisolariciresinol and oligolignans and optionally betulonic or betulinic acid in a 5 concentration of about 30 pM.
According to certain embodiment the daily dosage of the extract is such that it contains 100-200 mg of 7-hydroxymatairesinol, 4-8 mg each of the following lignans scoisolariciresinol, condendrin, liovil, lariciresinol, and 4-20 mg other lignans including oligolignans.
10 The embodiments of the present invention relate to the use of a composition including at a range of 1-50 wt%, preferably at a range of 5-50 wt% of a lignan mixture including at least following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers thereof along with oligolingnans and optionally betulonic or betulinic acid for lowering, suppressing, and 15 .. thereby inhibiting, in vitro, the proliferation and growth of mammalian cancer cells. As used herein this disclosure, the percent ranges given for the lignan mixture specifically refers to percent by weight of the total composition.
To be more exact, the particular embodiments of the present invention relate to i) a composition, ii) methods of preparing the composition, and iii) methods of using the
20 .. composition for suppressing, and thereby, inhibiting the growth and/or proliferation of at least prostate and melanoma cancer cells, in vitro. This includes a lignan mixture including at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers thereof and a fraction including oligolignans and optionally betulonic or betulinic acid in a combination with an extraction solution, selected from the group consisting of alcohol and water-alcohol mixture, the balance being a physiologically acceptable carrier agent.
According to certain embodiments, the in vitro activity of lignan extracts may be used in selecting proper lignan extract with specific lignan concentration for preparation a treatment for use in suppressing tumor growth in a patient diagnosed with tumor.
One essential aspect of the particular embodiments of the present invention is also to make wood lignans available, in such a level, in an edible food product or as a supplement
According to certain embodiments, the in vitro activity of lignan extracts may be used in selecting proper lignan extract with specific lignan concentration for preparation a treatment for use in suppressing tumor growth in a patient diagnosed with tumor.
One essential aspect of the particular embodiments of the present invention is also to make wood lignans available, in such a level, in an edible food product or as a supplement
21 that their concentration is high enough so as to ensure, that their beneficial cancer abolishing lowering effect will appear. Normal wood material contains only small amounts of wood lignans and making food supplements from this kind of wood material would be cumbersome and ineffective. However, wood bark and/or knot wood have been found to include much higher amounts of these lignans in order to make the aforementioned lignan mixture possible.
Therefore, another essential aspect of the present invention relates to a method for preparing a composition for use in suppressing, and thereby eradicating cancer cells, including prostate and melanoma cancer cells by using wood bark and/or knot wood, as a source of obtaining the lignans. The method for making the compositions includes a) extracting the lignan mixture from a wood bark and/or knot wood from one or more coniferous species selected from at least the genus Picea and Abies, with an extraction solution selected from the group consisting of an alcohol and an alcohol-water mixture;
b) obtaining a mixture of alcohol-wood lignan mixture or an alcohol-water-wood lignan; c) optionally adding betulinic or betulonic acid, and d) adding a physiologically and pharmaceutically acceptable carrier agent to said mixture.
The present invention also relates to a food additive, nutraceutical or dietary supplement for use in methods for suppressing the growth of tumors, including colon cancer tumors, brain cancer tumors, prostate cancer tumors, and breast cancer tumors of mammals.
Particular embodiments of the present invention relate to a use of a composition as a dietary supplement or an additive for a food product capable of suppressing the growth and/or proliferation of cancer cells and tumor growth in vivo, the composition comprising at a range of 1-50 wt%, preferably 5-50 wt% a lignan mixture including at least following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers thereof as well as a fraction of oligolignans and optionally betulonic and/or betulinic acid in combination with an edible solid or liquid carrier material.
Preferably, the composition may include at a range of 1-90 wt%, preferably at a range of 5-90 wt%, the lignan mixture in a combination with an extraction solution selected from the group consisting of alcohol and water-alcohol mixture, the balance being an edible solid or a liquid carrier material.
Therefore, another essential aspect of the present invention relates to a method for preparing a composition for use in suppressing, and thereby eradicating cancer cells, including prostate and melanoma cancer cells by using wood bark and/or knot wood, as a source of obtaining the lignans. The method for making the compositions includes a) extracting the lignan mixture from a wood bark and/or knot wood from one or more coniferous species selected from at least the genus Picea and Abies, with an extraction solution selected from the group consisting of an alcohol and an alcohol-water mixture;
b) obtaining a mixture of alcohol-wood lignan mixture or an alcohol-water-wood lignan; c) optionally adding betulinic or betulonic acid, and d) adding a physiologically and pharmaceutically acceptable carrier agent to said mixture.
The present invention also relates to a food additive, nutraceutical or dietary supplement for use in methods for suppressing the growth of tumors, including colon cancer tumors, brain cancer tumors, prostate cancer tumors, and breast cancer tumors of mammals.
Particular embodiments of the present invention relate to a use of a composition as a dietary supplement or an additive for a food product capable of suppressing the growth and/or proliferation of cancer cells and tumor growth in vivo, the composition comprising at a range of 1-50 wt%, preferably 5-50 wt% a lignan mixture including at least following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers thereof as well as a fraction of oligolignans and optionally betulonic and/or betulinic acid in combination with an edible solid or liquid carrier material.
Preferably, the composition may include at a range of 1-90 wt%, preferably at a range of 5-90 wt%, the lignan mixture in a combination with an extraction solution selected from the group consisting of alcohol and water-alcohol mixture, the balance being an edible solid or a liquid carrier material.
22 The spectrum of effect of lignan mixture can be widened by adding other wood lignans or triterpenes having for example different antimicrobial potency than the mentioned lignan mixture. As is shown here, adding low concentration of betulonic or betulinic acid provides an improved reduction of cancer cell proliferation.
The composition may preferably be formulated, such that, the lignan mixture and a carrier material form together an encapsulated liquid, powder or pill, or a solution or a suspension.
According to certain embodiments the compositions of this disclosure may be used in combination with various medical cancer treatments, such as radiation- or chemotherapy.
In certain embodiments, the compositions are used during the radiation- or chemotherapy treatment; in certain other embodiments the composition are used after cessation of radiation- or chemotherapy.
Certain further embodiments are related to a method for decreasing the risk of cancers in a mammal in general, the method including administering orally a dietary supplement of any one of the previously mentioned embodiments to a mammal on daily basis.
Examples Example 1 ¨ Preparation and extraction of a lignan extract with an extraction solution containing propylene glycol A concentrated alcohol-wood lignan extract was prepared by extracting chipped knot wood of Picea abies L. with an extraction solution composed of propylene glycol. The extract contained 7.5 wt% of the following lignans:
Table 1: Lignan content of an extract of Picea abies L.:
Lignan Amount, wt%
Hydroxymatairesimol 5-6 Secoisolariciresinol 0.2-0.4
The composition may preferably be formulated, such that, the lignan mixture and a carrier material form together an encapsulated liquid, powder or pill, or a solution or a suspension.
According to certain embodiments the compositions of this disclosure may be used in combination with various medical cancer treatments, such as radiation- or chemotherapy.
In certain embodiments, the compositions are used during the radiation- or chemotherapy treatment; in certain other embodiments the composition are used after cessation of radiation- or chemotherapy.
Certain further embodiments are related to a method for decreasing the risk of cancers in a mammal in general, the method including administering orally a dietary supplement of any one of the previously mentioned embodiments to a mammal on daily basis.
Examples Example 1 ¨ Preparation and extraction of a lignan extract with an extraction solution containing propylene glycol A concentrated alcohol-wood lignan extract was prepared by extracting chipped knot wood of Picea abies L. with an extraction solution composed of propylene glycol. The extract contained 7.5 wt% of the following lignans:
Table 1: Lignan content of an extract of Picea abies L.:
Lignan Amount, wt%
Hydroxymatairesimol 5-6 Secoisolariciresinol 0.2-0.4
23 Conidendrin 0.2-0.4 Liovil 0.2-0.4 Lariciresinol 0.1-0.2 Other lignans, including oligolignans 0.2-1 5 In certain cases, the extract was 'fortified' by adding betulonic and/or betulinic acid to the extract such that the betulonic and/or betulinic acid concentration in the final composition was 10-100 pM.
Example 2 ¨ Preparation and extraction of a lignan extract with an extraction solution containing ethanol and water A concentrated alcohol-wood extract containing a lignan mixture presented in Table 1 was prepared by extracting chipped knot wood of Picea abies L., with an extraction solution composed of ethanol and water. The alcohol-water wood extract contained 75 wt% of the lignan mixture presented in Table 1.
In certain cases, the extract was 'fortified' by adding betulonic and/ or betulinic acid to the extract such that the betulonic and/or betulinic acid concentration in the final composition was 10-100 pM.
Example 3 ¨ Treatment of androgen independent prostate cancer cells with lignan extracts, in vitro, suppresses the proliferation of the prostate cancer cells Lignan extract An alcohol-water wood extract was prepared from chipped knot wood of Picea abies L by extracting the wood with ethanol-water extraction solution. The extract contained 7.5% of the lignan mixture presented in table 1 above. A composition was prepared by mixing 10 wt% of the ethanol-water wood extract with 90 wt% of 1,3-propanediol. This composition was used in the experiments below and is below called 'the lignan extract'. A
dilution
Example 2 ¨ Preparation and extraction of a lignan extract with an extraction solution containing ethanol and water A concentrated alcohol-wood extract containing a lignan mixture presented in Table 1 was prepared by extracting chipped knot wood of Picea abies L., with an extraction solution composed of ethanol and water. The alcohol-water wood extract contained 75 wt% of the lignan mixture presented in Table 1.
In certain cases, the extract was 'fortified' by adding betulonic and/ or betulinic acid to the extract such that the betulonic and/or betulinic acid concentration in the final composition was 10-100 pM.
Example 3 ¨ Treatment of androgen independent prostate cancer cells with lignan extracts, in vitro, suppresses the proliferation of the prostate cancer cells Lignan extract An alcohol-water wood extract was prepared from chipped knot wood of Picea abies L by extracting the wood with ethanol-water extraction solution. The extract contained 7.5% of the lignan mixture presented in table 1 above. A composition was prepared by mixing 10 wt% of the ethanol-water wood extract with 90 wt% of 1,3-propanediol. This composition was used in the experiments below and is below called 'the lignan extract'. A
dilution
24 series of the extract was prepared have concentrations of 24, 36, and 60, pM
of the extract.
Live-cell imaging The cells were cultured in either RPMI-1640 (PC-3) or DMEM media (SK-Mel-5, WM-4 & A2058) supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/mL
penicillin, and 100 pg/mL streptomycin. One day prior to the treatment, the cells were counted and plated on glass coverslips on 24-well plates (Falcon) and incubated overnight at +37 C (5% CO2), in order for the cells to attach to the coverslips. The following day, the cells were washed with Dulbecco's phosphate buffered saline (Bio West) and treated with 24, 36 or 60 pM of a lignan extract (Oy Granula Ab Ltd.) or solvent control (1,3-propanediol). Additionally, a control using only growth media was used. All samples were made in triplicates. The cells were imaged for 48h with 2h intervals (9 images per well) using IncuCyte S3 Live-Cell Analysis System (Essen BioScience). From live-cell imaging, both videos and graphs showing cell growth could be attained. The experiments were repeated at least three individual times.
Phase contrast imaging Both the prostate cancer and the melanoma cell lines were cultured, plated, and treated as previously described with varying concentrations of the mixture of lignan extracts (24 pM, 36 pM, 60 pM). Phase contrast images of treated cells were taken after 24h and 48h incubation at +37 C (5% CO2) using a Zeiss Axio Vert. Al microscope with 20x and 5x magnifications. All samples were in triplicates on 24-well plates and the experiment was repeated at least three independent times.
Prostate cancer cells were analyzed for cell proliferation after being treated with the lignan extract in different concentrations. When taking still images after 24h and 48h after treatment with 24 pM lignan extract, clear differences in the total amount of living cells in the wells could be noted for PC-3 cells (FIG. 1B). No apparent change in the cell amount between the two controls could be observed (FIG. IA and FIG. 1C).
Additionally, some slight morphological changes could be seen in the cultured cells between treated and control cells (FIGs. 2A-2C). These changes were mostly a decreased abundance of actively dividing cells and an increase in senescent-like cells (FIG. 2C).
Only pictures of cells treated with 24 pM lignan extract (48h) are shown in this disclosure.
These results were confirmed when assessing the proliferation pattern of PC-3 cells, as the lignan extract had a dose-dependent response, thereby suppressing and inhibiting 5 the growth and proliferation of the PC3, when used in a concentration ranging from 24-60 M, as clearly depicted in FIG. 3A and 3B.
Statistical analysis of data at incubation time 48 hours was calculated and performed with one-way ANOVA and Dunnett's multiple comparisons test using GraphPad Prism 6 software. Significant effects were found with 60 M lignan extract treatment, where P <
10 0.05 was considered to indicate significant differences in the data.
During the 48h live-cell imaging, a notable suppression in the proliferation rate was found with PC-3 cells, as described hereinabove, using 24-60 pM lignan extract (FIG.
3A, blue, orange, and red graphs). Since the effect of lignans is concentration-dependent (FIG. 3A), with high concentration of 60 pM (red curve), PC-3 cells lost almost completely their 15 capability of growth within the first 10-24h of the treatment (FIG. 3A).
With concentrations of 24 pM (orange) and 36 pM (blue), there was a clear effect on the growth rates, but the growth was not fully lost. As expected, the solvent control 1,3-propanediol did not have any effect on the PC-3 prostate cancer cells nor to their growth (light and dark grey graphs FIG. 3A and 3B).
Example 4 Cytotoxicity assay of P. abies knotwood extract on serum-starved PC-cells Lignan extract An alcohol-water wood extract was prepared from chipped knot wood of Picea abies L by extracting the wood with alcohol-water (e.g. ethanol-water) extraction solution. The extract contained 7.5% of the lignan mixture presented in table 1 above. A
composition was prepared by mixing 10 wt% of the alcohol-water wood extract with 90 wt% of 1,3-propanediol. This composition was used in the experiments below and is below called 'the lignan extract'. A dilution series of the extract was prepared have concentrations of 10, 15, 20, 25, 30, 40, 50, 60 and 70 pM of the extract.
Cell culture PC-3 cells were seeded with 10 000 cells/well on a 96-well plate (Falcon) in medium (Sigma-Aldrich) supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/m1 penicillin, and 100 g/m1 streptomycin. The cells were let attach for 6h prior to changing the medium to serum-free RPMI-1640 and incubating them overnight in +37 C, 5 % CO2. After overnight serum starvation, cells were treated with P. abies knotwood extract in concentrations of 0-70 M in serum-free medium in replicate samples and incubated for 24h. The old medium was thereafter discarded and substituted with 100 L
10 % Cell Counting Kit-8 reagent (Dojindo Molecular Technologies) diluted in serum-free RPMI-1640 medium. The samples were incubated for an additional lh prior to analyzing cell viability by measuring the absorbance at 450 nm using a microplate reader (Hidex Sense) according to manufacturer's protocol. Non-treated cells were used as a negative control. The experiment was repeated at least three independent times for accurate cytotoxicity analysis. The IC50-value was calculated using GraphPad Prism 6 software.
Figure 3C shows the extract inducing significant cell death in PC-3 cells under growth factor scarce condition. The graph represents mean values of viability ( SEM) from the independent experiment repeats normalized to the non-treated control sample where viability was set to 100 %.
A cytotoxicity assay measuring cell viability of serum-starved PC-3 cells treated for 24h with extract in serum-free medium revealed the IC50-value to be 20.02 M in these treatment conditions. Cell death could be observed already at low concentrations of <10 M and the toxicity became more profound with increasing doses, indicating that the cells become sensitized to the extract when growth factors are limited. Growth factor depletion in vitro mimics to an extent the conditions in vivo, such as in a solid tumor where the amount of available circulating growth factors is poor.
Example 5 Melanoma cancer cells are less responsive in vitro to lignan extract treatment than androgen independent prostate cancer cells Concerning the experiments with the melanoma cancer cells, even if the lignan extract did have an effect on the proliferation rate of the cells, the effect was not as fast and strong as with prostate cancer cells. By looking at still images taken of the melanoma cell line SK-Mel-5, no clear repression of the cell growth, nor any morphological changes were observed with 24 pM lignan extract after 48h (FIGs. 4A-4C and FIGs. 5A-5C).
Similar results were obtained with A2058 and WM-266-4 cell lines (results not shown).
Referring to Figures 6A and 6B, the melanoma cell line WM-266-4 was much more resistant than PC-3 cells to the effects of the extract as seen during 48h treatment with live-cell imaging. Nonetheless, statistically significant repression on proliferation was seen with the highest concentration (60 pM). However, the observed effects started to show first after 24h of treatment, whereas clear suppression of cell division could be seen much earlier with PC-3 cells. Naturally, prostate cancer and melanoma cells behave in a significantly different fashion as e.g. their surface membrane receptors and signal transduction pathways vary to an extent. For these and other reasons, the two types of cancer cells are not exactly comparable to each other. Cell cycle initiation and progression is however regulated generally in a similar way in all human cell types. As with PC-3 cells, key proteins involved in cell cycle regulation seem to be affected also in WM-266-4 cells.
Again, statistical analysis of data at incubation time 48 hours was calculated and performed with one-way ANOVA and Dunnett's multiple comparisons test by using GraphPad Prism 6 software. Significant effects were found with 60 M lignan extract treatment, where P< 0.05 was considered to indicate significant differences in the data.
In conclusion, the experiments show that exposure to a lignan mixture of this disclosure results in repression of cell proliferation of various cancer cell lines generally in time and concentration dependent manner.
Example 6 The lignan extract treatment of androgen independent prostate cancer cells prevents their proliferation by arresting the cell cycle in GO/G1 phase Flow cytometry analysis of cell cycle arrest using pro pidium iodide staining PC-3 cells were seeded on 6-well plates (Falcon) with 200 000 cells/well in medium (Sigma Aldrich) supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/m1 penicillin, and 100 mg/ml streptomycin and incubated in +37 C 5% CO2 overnight. The next day cells were treated with the Picea abies lignan extract in concentrations of 0, 24 and 60 pM and incubated for an additional for 24h.
Cells were harvested thereafter by trypsinization and centrifuged down (1200 rpm for 5 min in +4 C), after which the pellets were resuspended in Dulbecco's phosphate buffered saline (BioWest). The samples were fixed for 15 min at RT using Cytofix/CytopermTM
(BD
Bioscience). After fixation, the cells were pelleted and washed with in lx BD
Perm/WashTM buffer (diluted in distilled water). The pellets were resuspended gently in FxCycle PURNase Staining Solution (ThermoFisher Scientific) and incubated for 30 min at RT in the dark in order to stain the cells. Once stained, the samples were spun down and the pellets were resuspended in FACS buffer (2% fetal bovine serum + 0.4%
0.5 M
EDTA in PBS) prior to analyzing them using flow cytometry (BD LSR Fortessa analyzer).
At least 20 000 events per sample were collected for the analysis.
Statistical analysis The statistical analysis of the data was calculated by one-way ANOVA
complemented with Tukey's multiple comparison test by using the GraphPad Prism 6 software.
P < 0.05 was considered to indicate significant differences in the data. The graphs represent the percentage of cells in each cell cycle phase from three independent experiments standard error of the mean (SEM).
Figures 7 A-D show results of these experiments. Cell cycle analysis using propidium iodide staining of lignan extract treated cells showed significant differences in the proportion of cell in the various stages of the cell cycle. PC-3 cells arrested in the GO/G1-phase upon 24h treatment already with 24 pM concentrations of the extract. By arresting in GO/G1, a smaller percentage of cells were evidently operating in both the S-and the G2/M-phase, where significant differences could be noted between treated and untreated samples in the G2/M-phase. Interestingly, no clear difference was seen between 24 pM
and 60 pM treatments unlike in previously performed live-cell imaging, where treatment with 60 pM caused a significant suppression in proliferation.
These results give support to an embodiment of using the extract of this invention in early phases of tumor development.
Example 7 Low concentrations of Betulinic acid (BA) or Betulonic acid (BOA) in the extract improve suppression of proliferation of metastatic prostate cancer (PC-3) and metastatic melanoma (WM-266-4) cells during 48h treatment Lignan extract An alcohol-water wood extract was prepared from chipped knot wood of Picea abies L by extracting the wood with ethanol-water extraction solution. The extract contained 7.5% of the lignan mixture presented in table 1 above. A composition was prepared by mixing 10 wt% of the ethanol-water wood extract with 90 wt% of 1,3-propanediol. This composition was used in the experiments below and is below called 'the lignan extract'. A
dilution series of the extract was prepared have concentrations of 20, 40, and 60 M of the extract.
1% DMSO was used to control for the toxicity effects of the solvent only on cell viability.
Betulinic acid and betulonic acid stock solutions were diluted in DMSO. The concentration of DMSO per sample in each experiment was 1%.
Live-cell imaging The cells were cultured in either RPMI-1640 (PC-3) or DMEM media (WM-266-4) supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/mL
penicillin, and 100 g/mL streptomycin. One day prior to the treatment, the cells were counted and plated on 24-well plates (Falcon) and incubated overnight at +37 C (5% CO2).
The following day, the cells were treated betulinic acid (BA) or betulonic acid (BOA) in concentrations of 0, 10, 50, 70, 100, and 150 M. 1 % DMSO was used to control for the effects of the solvent. All samples were made in triplicates. The cells were imaged for 48h with 2h intervals (9 images per well) using IncuCyte S3 Live-Cell Analysis System (Essen BioScience).
Cancer cells were analyzed for cell proliferation after being treated with BA
or BOA in different concentrations for 48h. Figure 9A shows clearly how addition of as low as 10 uM
BA clearly decreased the proliferation of PC-3 prostate cancer cells. The effect was enhanced with higher concentraionts of 50, 70, 100 and 150 uM BA. The maximum 5 decrease of the proliferation was achieved by 50 uM BA and increase of the BA
concentration beyond this did not have any further effect during the 48-hour treatment period. Figure 9B show similar result with melanoma cells WM-266-4: addition of 50 uM
BOA gave the maximal decrease in proliferation and increase of BOA
concentration above this did not have any further effect. Figure 9C shows similar results with PC-3 cells 10 treated with BOA, where addition of 50 uM BOA gave the maximal decrease in proliferation and concentrations beyond this did not further enhance the effects.
These results were confirmed by determining viability of the cells treated with extract with various BA or BOA concentrations.
Cell culture and cytotoxicity assay of BA and BOA
15 Cells were seeded with 5000 cells/well on a 96-well plate (Falcon) in RPMI-1640 medium (PC-3 cells) or DMEM medium (WM-266-4 cells) supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/m1 penicillin, and 100 jig/ml streptomycin. The cells were incubating overnight in +37 C, 5 % CO2 for the cells to adhere to the plate. The following day, cells were treated with BA or BOA (prepared from stock solutions using 20 DMSO as solvent) in concentrations of 0-200 uM in complete medium in replicate samples and incubated for 48h. The old medium was thereafter discarded and substituted with 100 uL 10 % Cell Counting Kit-8 reagent (Dojindo Molecular Technologies) diluted in serum-free RPMI-1640 medium. The samples were incubated for an additional lh prior to analyzing cell viability by measuring the absorbance at 450 nm using a microplate
of the extract.
Live-cell imaging The cells were cultured in either RPMI-1640 (PC-3) or DMEM media (SK-Mel-5, WM-4 & A2058) supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/mL
penicillin, and 100 pg/mL streptomycin. One day prior to the treatment, the cells were counted and plated on glass coverslips on 24-well plates (Falcon) and incubated overnight at +37 C (5% CO2), in order for the cells to attach to the coverslips. The following day, the cells were washed with Dulbecco's phosphate buffered saline (Bio West) and treated with 24, 36 or 60 pM of a lignan extract (Oy Granula Ab Ltd.) or solvent control (1,3-propanediol). Additionally, a control using only growth media was used. All samples were made in triplicates. The cells were imaged for 48h with 2h intervals (9 images per well) using IncuCyte S3 Live-Cell Analysis System (Essen BioScience). From live-cell imaging, both videos and graphs showing cell growth could be attained. The experiments were repeated at least three individual times.
Phase contrast imaging Both the prostate cancer and the melanoma cell lines were cultured, plated, and treated as previously described with varying concentrations of the mixture of lignan extracts (24 pM, 36 pM, 60 pM). Phase contrast images of treated cells were taken after 24h and 48h incubation at +37 C (5% CO2) using a Zeiss Axio Vert. Al microscope with 20x and 5x magnifications. All samples were in triplicates on 24-well plates and the experiment was repeated at least three independent times.
Prostate cancer cells were analyzed for cell proliferation after being treated with the lignan extract in different concentrations. When taking still images after 24h and 48h after treatment with 24 pM lignan extract, clear differences in the total amount of living cells in the wells could be noted for PC-3 cells (FIG. 1B). No apparent change in the cell amount between the two controls could be observed (FIG. IA and FIG. 1C).
Additionally, some slight morphological changes could be seen in the cultured cells between treated and control cells (FIGs. 2A-2C). These changes were mostly a decreased abundance of actively dividing cells and an increase in senescent-like cells (FIG. 2C).
Only pictures of cells treated with 24 pM lignan extract (48h) are shown in this disclosure.
These results were confirmed when assessing the proliferation pattern of PC-3 cells, as the lignan extract had a dose-dependent response, thereby suppressing and inhibiting 5 the growth and proliferation of the PC3, when used in a concentration ranging from 24-60 M, as clearly depicted in FIG. 3A and 3B.
Statistical analysis of data at incubation time 48 hours was calculated and performed with one-way ANOVA and Dunnett's multiple comparisons test using GraphPad Prism 6 software. Significant effects were found with 60 M lignan extract treatment, where P <
10 0.05 was considered to indicate significant differences in the data.
During the 48h live-cell imaging, a notable suppression in the proliferation rate was found with PC-3 cells, as described hereinabove, using 24-60 pM lignan extract (FIG.
3A, blue, orange, and red graphs). Since the effect of lignans is concentration-dependent (FIG. 3A), with high concentration of 60 pM (red curve), PC-3 cells lost almost completely their 15 capability of growth within the first 10-24h of the treatment (FIG. 3A).
With concentrations of 24 pM (orange) and 36 pM (blue), there was a clear effect on the growth rates, but the growth was not fully lost. As expected, the solvent control 1,3-propanediol did not have any effect on the PC-3 prostate cancer cells nor to their growth (light and dark grey graphs FIG. 3A and 3B).
Example 4 Cytotoxicity assay of P. abies knotwood extract on serum-starved PC-cells Lignan extract An alcohol-water wood extract was prepared from chipped knot wood of Picea abies L by extracting the wood with alcohol-water (e.g. ethanol-water) extraction solution. The extract contained 7.5% of the lignan mixture presented in table 1 above. A
composition was prepared by mixing 10 wt% of the alcohol-water wood extract with 90 wt% of 1,3-propanediol. This composition was used in the experiments below and is below called 'the lignan extract'. A dilution series of the extract was prepared have concentrations of 10, 15, 20, 25, 30, 40, 50, 60 and 70 pM of the extract.
Cell culture PC-3 cells were seeded with 10 000 cells/well on a 96-well plate (Falcon) in medium (Sigma-Aldrich) supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/m1 penicillin, and 100 g/m1 streptomycin. The cells were let attach for 6h prior to changing the medium to serum-free RPMI-1640 and incubating them overnight in +37 C, 5 % CO2. After overnight serum starvation, cells were treated with P. abies knotwood extract in concentrations of 0-70 M in serum-free medium in replicate samples and incubated for 24h. The old medium was thereafter discarded and substituted with 100 L
10 % Cell Counting Kit-8 reagent (Dojindo Molecular Technologies) diluted in serum-free RPMI-1640 medium. The samples were incubated for an additional lh prior to analyzing cell viability by measuring the absorbance at 450 nm using a microplate reader (Hidex Sense) according to manufacturer's protocol. Non-treated cells were used as a negative control. The experiment was repeated at least three independent times for accurate cytotoxicity analysis. The IC50-value was calculated using GraphPad Prism 6 software.
Figure 3C shows the extract inducing significant cell death in PC-3 cells under growth factor scarce condition. The graph represents mean values of viability ( SEM) from the independent experiment repeats normalized to the non-treated control sample where viability was set to 100 %.
A cytotoxicity assay measuring cell viability of serum-starved PC-3 cells treated for 24h with extract in serum-free medium revealed the IC50-value to be 20.02 M in these treatment conditions. Cell death could be observed already at low concentrations of <10 M and the toxicity became more profound with increasing doses, indicating that the cells become sensitized to the extract when growth factors are limited. Growth factor depletion in vitro mimics to an extent the conditions in vivo, such as in a solid tumor where the amount of available circulating growth factors is poor.
Example 5 Melanoma cancer cells are less responsive in vitro to lignan extract treatment than androgen independent prostate cancer cells Concerning the experiments with the melanoma cancer cells, even if the lignan extract did have an effect on the proliferation rate of the cells, the effect was not as fast and strong as with prostate cancer cells. By looking at still images taken of the melanoma cell line SK-Mel-5, no clear repression of the cell growth, nor any morphological changes were observed with 24 pM lignan extract after 48h (FIGs. 4A-4C and FIGs. 5A-5C).
Similar results were obtained with A2058 and WM-266-4 cell lines (results not shown).
Referring to Figures 6A and 6B, the melanoma cell line WM-266-4 was much more resistant than PC-3 cells to the effects of the extract as seen during 48h treatment with live-cell imaging. Nonetheless, statistically significant repression on proliferation was seen with the highest concentration (60 pM). However, the observed effects started to show first after 24h of treatment, whereas clear suppression of cell division could be seen much earlier with PC-3 cells. Naturally, prostate cancer and melanoma cells behave in a significantly different fashion as e.g. their surface membrane receptors and signal transduction pathways vary to an extent. For these and other reasons, the two types of cancer cells are not exactly comparable to each other. Cell cycle initiation and progression is however regulated generally in a similar way in all human cell types. As with PC-3 cells, key proteins involved in cell cycle regulation seem to be affected also in WM-266-4 cells.
Again, statistical analysis of data at incubation time 48 hours was calculated and performed with one-way ANOVA and Dunnett's multiple comparisons test by using GraphPad Prism 6 software. Significant effects were found with 60 M lignan extract treatment, where P< 0.05 was considered to indicate significant differences in the data.
In conclusion, the experiments show that exposure to a lignan mixture of this disclosure results in repression of cell proliferation of various cancer cell lines generally in time and concentration dependent manner.
Example 6 The lignan extract treatment of androgen independent prostate cancer cells prevents their proliferation by arresting the cell cycle in GO/G1 phase Flow cytometry analysis of cell cycle arrest using pro pidium iodide staining PC-3 cells were seeded on 6-well plates (Falcon) with 200 000 cells/well in medium (Sigma Aldrich) supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/m1 penicillin, and 100 mg/ml streptomycin and incubated in +37 C 5% CO2 overnight. The next day cells were treated with the Picea abies lignan extract in concentrations of 0, 24 and 60 pM and incubated for an additional for 24h.
Cells were harvested thereafter by trypsinization and centrifuged down (1200 rpm for 5 min in +4 C), after which the pellets were resuspended in Dulbecco's phosphate buffered saline (BioWest). The samples were fixed for 15 min at RT using Cytofix/CytopermTM
(BD
Bioscience). After fixation, the cells were pelleted and washed with in lx BD
Perm/WashTM buffer (diluted in distilled water). The pellets were resuspended gently in FxCycle PURNase Staining Solution (ThermoFisher Scientific) and incubated for 30 min at RT in the dark in order to stain the cells. Once stained, the samples were spun down and the pellets were resuspended in FACS buffer (2% fetal bovine serum + 0.4%
0.5 M
EDTA in PBS) prior to analyzing them using flow cytometry (BD LSR Fortessa analyzer).
At least 20 000 events per sample were collected for the analysis.
Statistical analysis The statistical analysis of the data was calculated by one-way ANOVA
complemented with Tukey's multiple comparison test by using the GraphPad Prism 6 software.
P < 0.05 was considered to indicate significant differences in the data. The graphs represent the percentage of cells in each cell cycle phase from three independent experiments standard error of the mean (SEM).
Figures 7 A-D show results of these experiments. Cell cycle analysis using propidium iodide staining of lignan extract treated cells showed significant differences in the proportion of cell in the various stages of the cell cycle. PC-3 cells arrested in the GO/G1-phase upon 24h treatment already with 24 pM concentrations of the extract. By arresting in GO/G1, a smaller percentage of cells were evidently operating in both the S-and the G2/M-phase, where significant differences could be noted between treated and untreated samples in the G2/M-phase. Interestingly, no clear difference was seen between 24 pM
and 60 pM treatments unlike in previously performed live-cell imaging, where treatment with 60 pM caused a significant suppression in proliferation.
These results give support to an embodiment of using the extract of this invention in early phases of tumor development.
Example 7 Low concentrations of Betulinic acid (BA) or Betulonic acid (BOA) in the extract improve suppression of proliferation of metastatic prostate cancer (PC-3) and metastatic melanoma (WM-266-4) cells during 48h treatment Lignan extract An alcohol-water wood extract was prepared from chipped knot wood of Picea abies L by extracting the wood with ethanol-water extraction solution. The extract contained 7.5% of the lignan mixture presented in table 1 above. A composition was prepared by mixing 10 wt% of the ethanol-water wood extract with 90 wt% of 1,3-propanediol. This composition was used in the experiments below and is below called 'the lignan extract'. A
dilution series of the extract was prepared have concentrations of 20, 40, and 60 M of the extract.
1% DMSO was used to control for the toxicity effects of the solvent only on cell viability.
Betulinic acid and betulonic acid stock solutions were diluted in DMSO. The concentration of DMSO per sample in each experiment was 1%.
Live-cell imaging The cells were cultured in either RPMI-1640 (PC-3) or DMEM media (WM-266-4) supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/mL
penicillin, and 100 g/mL streptomycin. One day prior to the treatment, the cells were counted and plated on 24-well plates (Falcon) and incubated overnight at +37 C (5% CO2).
The following day, the cells were treated betulinic acid (BA) or betulonic acid (BOA) in concentrations of 0, 10, 50, 70, 100, and 150 M. 1 % DMSO was used to control for the effects of the solvent. All samples were made in triplicates. The cells were imaged for 48h with 2h intervals (9 images per well) using IncuCyte S3 Live-Cell Analysis System (Essen BioScience).
Cancer cells were analyzed for cell proliferation after being treated with BA
or BOA in different concentrations for 48h. Figure 9A shows clearly how addition of as low as 10 uM
BA clearly decreased the proliferation of PC-3 prostate cancer cells. The effect was enhanced with higher concentraionts of 50, 70, 100 and 150 uM BA. The maximum 5 decrease of the proliferation was achieved by 50 uM BA and increase of the BA
concentration beyond this did not have any further effect during the 48-hour treatment period. Figure 9B show similar result with melanoma cells WM-266-4: addition of 50 uM
BOA gave the maximal decrease in proliferation and increase of BOA
concentration above this did not have any further effect. Figure 9C shows similar results with PC-3 cells 10 treated with BOA, where addition of 50 uM BOA gave the maximal decrease in proliferation and concentrations beyond this did not further enhance the effects.
These results were confirmed by determining viability of the cells treated with extract with various BA or BOA concentrations.
Cell culture and cytotoxicity assay of BA and BOA
15 Cells were seeded with 5000 cells/well on a 96-well plate (Falcon) in RPMI-1640 medium (PC-3 cells) or DMEM medium (WM-266-4 cells) supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/m1 penicillin, and 100 jig/ml streptomycin. The cells were incubating overnight in +37 C, 5 % CO2 for the cells to adhere to the plate. The following day, cells were treated with BA or BOA (prepared from stock solutions using 20 DMSO as solvent) in concentrations of 0-200 uM in complete medium in replicate samples and incubated for 48h. The old medium was thereafter discarded and substituted with 100 uL 10 % Cell Counting Kit-8 reagent (Dojindo Molecular Technologies) diluted in serum-free RPMI-1640 medium. The samples were incubated for an additional lh prior to analyzing cell viability by measuring the absorbance at 450 nm using a microplate
25 reader (Hidex Sense) according to manufacturer's protocol. Non-treated cells were used as a negative control. 1% DMSO was used to control for effect of solvent. All samples contained 1 (:)/0 or less DMSO. The experiment was repeated at least three independent times for accurate cytotoxicity analysis. The IC50-value was calculated using GraphPad Prism 6 software.
Figure 10 A and B show the viability test of WM266-4 cells and PC-3 cells (respectively) treated 48 hours with various concentrations of BA. In both cases the viability of the cells dropped to close to 0% when treated with 100 uM BA for 48 hours. IC50-value for BA on WM-266-4 cells was 64.67 M, whereas for PC-3 cells the value was 67.95 uM as calculated using GraphPad Prism 6 software.
Figures 11 A and B show the viability test of PC-3 cells and WM-266-4 cells (respectively) when treated 48 hours with various concentrations of BOA. In both case the viability decreased below 20% with 100 pM BOA treatment, but WM-266-4 cells were more responsive to lower BOA concentrations than PC-3 cells. IC50-value for BOA on 4 cells was 39.83 M, whereas for PC-3 cells the value was 78.47 uM as calculated using GraphPad Prism 6 software.
Example 8 Synergistic effect of lignan extract and betulonic acid or betulinic acid Live-cell imaging The cells were cultured in either RPMI-1640 (PC-3) or DMEM media (WM-266-4) supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/mL
penicillin, and 100 ug/mL streptomycin. One day prior to the treatment, the cells were counted and plated on 96-well plates (Falcon) and incubated overnight at +37 C (5% CO2).
The following day, the cells were treated with P. abies lignan extract in concentrations of 0, 20, 40 or 60 uM in combination with betulinic acid (BA) or betulonic acid (BOA) in concentrations of 0, 10, or 30 M. The cells were imaged for 48h with 2h intervals (4 images per well) using IncuCyte S3 Live-Cell Analysis System (Essen BioScience).
DMSO was tested to control for the effects of the solvent used for BA and BOA
stock solutions. 1,3-Propanediol was used to control for extract solvent. All samples were made in triplicates.
Figure 12 A illustrates end-point data from live-cell imaging experiments analyzing proliferation where prostate cancer cells were treated for 48 hours with either various concentrations of extract of Table 1, with various concentrations of BOA alone or with extract where various concentrations of BOA were added into it.
It can be seen that treatment with 40 or 60 pM extract alone decreased the proliferation in PC-3 cells. A slight enhancement of this suppression was achieved when BOA
was added to the extract in concentration of 10 or 30 M. Most dramatic decrease is achieved when the cells were treated with extract having BOA concentration of 30 pM.
Figure 12B shows similar experiment with PC-3 prostate cancer cells treated with the extract and BA. Again, most dramatic suppression of proliferation is seen when cells are treated with extract in combination with 30 pM BA.
Thus, it can be concluded that combination of the extract with BOA or BA
increases the toxic effects on PC-3 prostate cancer cells in vitro.
Figures 12 C and 12D show similar experiments with WM-266-4 melanoma cells treated with a combination of extract and BA or BOA. The most dramatic effect with is achieved by treating the cells with 40 pM extract having BOA concentration of 30 pM
(Fig. 12C). In case of BA (Figure 12D), the most dramatic effect is achieved with 20 pM
extract having added BA with concentration of 30 M.
The lignan extract alone has weaker effect on melanoma cancer cell growth than it has on prostate cancer cell growth as discussed in Example 5 above. However, adding BA
or BOA into the extract synergistically suppresses melanoma cell proliferation in a concentration-dependent manner.
The experiments show that combining extract with low concentrations of BA or BOA
sensitizes the cells for cell death or at least inhibit proliferation as is seen in the end-point data after 48 hours treatment for both PC-3 and WM-266-4 cells. Importantly, as is shown in Figure 8A and B neither BA or BOA had any significant effects on HDF cells in the concentrations used, indicating that the compounds are non-toxic to normal cells while being selectively toxic to melanoma and prostate cancer cells.
Example 10 Testimonial examples of effects of Lignan extract treatment on tumor growth A composition of lignan extract of Picea abies L. having lignan content of table 1 was administered orally daily to individuals having been diagnosed with tumor growth. 7-Hydroxymatairesinol concentration in the composition was 6.7mg/0.1m1. The daily dosage was 15-30 droplets per day and each droplet was about 10 microliters.
The extract was taken orally three times per day 5-10 droplets at a time.
Table 2 below illustrates the effects of the lignan extract treatment:
Individual Diagnosed Lignan Outcome Outcome condition treatment Female human Breast cancer; 20-30 droplets Lump No cancer a 6 mm lump in per day completely diagnosis after breast disappeared next follow up Female human Colon cancer; 30 droplets per Regained No cancer Kidney day appetite after 2 diagnosis after malfunction weeks of 15 months of treatment treatment Female human Brain tumor 30 droplets per Energized and No tumor found day lost headaches after 180 days after a few of treatment days of treatment Male human Enlarged 30 droplets Reduced need Loss of a prostate to urinate feeling of during painful nighttime after pressure a few days of treatment Female Dog Unknown About 15 Size of the Lumps cancer with droplets per lump reduced disappeared by day lumps in the to about half next chest within weeks appointment The above results are illustrative to show that the extract is effective to prevent cancer cell proliferation also in vivo. Cancer types that seem to be affected comprise at least breast cancer, brain cancer, and colon cancer. The extract is effective generally in mammals. There is also evidence that administering the composition topically (spray or ointment) heals burning injuries on skin caused by radiation treatment.
Topical administration can also be used as a preventive measure for injuries caused by radiation treatments.
Figure 10 A and B show the viability test of WM266-4 cells and PC-3 cells (respectively) treated 48 hours with various concentrations of BA. In both cases the viability of the cells dropped to close to 0% when treated with 100 uM BA for 48 hours. IC50-value for BA on WM-266-4 cells was 64.67 M, whereas for PC-3 cells the value was 67.95 uM as calculated using GraphPad Prism 6 software.
Figures 11 A and B show the viability test of PC-3 cells and WM-266-4 cells (respectively) when treated 48 hours with various concentrations of BOA. In both case the viability decreased below 20% with 100 pM BOA treatment, but WM-266-4 cells were more responsive to lower BOA concentrations than PC-3 cells. IC50-value for BOA on 4 cells was 39.83 M, whereas for PC-3 cells the value was 78.47 uM as calculated using GraphPad Prism 6 software.
Example 8 Synergistic effect of lignan extract and betulonic acid or betulinic acid Live-cell imaging The cells were cultured in either RPMI-1640 (PC-3) or DMEM media (WM-266-4) supplemented with 10 % fetal bovine serum, 2 mM L-glutamine, 100 U/mL
penicillin, and 100 ug/mL streptomycin. One day prior to the treatment, the cells were counted and plated on 96-well plates (Falcon) and incubated overnight at +37 C (5% CO2).
The following day, the cells were treated with P. abies lignan extract in concentrations of 0, 20, 40 or 60 uM in combination with betulinic acid (BA) or betulonic acid (BOA) in concentrations of 0, 10, or 30 M. The cells were imaged for 48h with 2h intervals (4 images per well) using IncuCyte S3 Live-Cell Analysis System (Essen BioScience).
DMSO was tested to control for the effects of the solvent used for BA and BOA
stock solutions. 1,3-Propanediol was used to control for extract solvent. All samples were made in triplicates.
Figure 12 A illustrates end-point data from live-cell imaging experiments analyzing proliferation where prostate cancer cells were treated for 48 hours with either various concentrations of extract of Table 1, with various concentrations of BOA alone or with extract where various concentrations of BOA were added into it.
It can be seen that treatment with 40 or 60 pM extract alone decreased the proliferation in PC-3 cells. A slight enhancement of this suppression was achieved when BOA
was added to the extract in concentration of 10 or 30 M. Most dramatic decrease is achieved when the cells were treated with extract having BOA concentration of 30 pM.
Figure 12B shows similar experiment with PC-3 prostate cancer cells treated with the extract and BA. Again, most dramatic suppression of proliferation is seen when cells are treated with extract in combination with 30 pM BA.
Thus, it can be concluded that combination of the extract with BOA or BA
increases the toxic effects on PC-3 prostate cancer cells in vitro.
Figures 12 C and 12D show similar experiments with WM-266-4 melanoma cells treated with a combination of extract and BA or BOA. The most dramatic effect with is achieved by treating the cells with 40 pM extract having BOA concentration of 30 pM
(Fig. 12C). In case of BA (Figure 12D), the most dramatic effect is achieved with 20 pM
extract having added BA with concentration of 30 M.
The lignan extract alone has weaker effect on melanoma cancer cell growth than it has on prostate cancer cell growth as discussed in Example 5 above. However, adding BA
or BOA into the extract synergistically suppresses melanoma cell proliferation in a concentration-dependent manner.
The experiments show that combining extract with low concentrations of BA or BOA
sensitizes the cells for cell death or at least inhibit proliferation as is seen in the end-point data after 48 hours treatment for both PC-3 and WM-266-4 cells. Importantly, as is shown in Figure 8A and B neither BA or BOA had any significant effects on HDF cells in the concentrations used, indicating that the compounds are non-toxic to normal cells while being selectively toxic to melanoma and prostate cancer cells.
Example 10 Testimonial examples of effects of Lignan extract treatment on tumor growth A composition of lignan extract of Picea abies L. having lignan content of table 1 was administered orally daily to individuals having been diagnosed with tumor growth. 7-Hydroxymatairesinol concentration in the composition was 6.7mg/0.1m1. The daily dosage was 15-30 droplets per day and each droplet was about 10 microliters.
The extract was taken orally three times per day 5-10 droplets at a time.
Table 2 below illustrates the effects of the lignan extract treatment:
Individual Diagnosed Lignan Outcome Outcome condition treatment Female human Breast cancer; 20-30 droplets Lump No cancer a 6 mm lump in per day completely diagnosis after breast disappeared next follow up Female human Colon cancer; 30 droplets per Regained No cancer Kidney day appetite after 2 diagnosis after malfunction weeks of 15 months of treatment treatment Female human Brain tumor 30 droplets per Energized and No tumor found day lost headaches after 180 days after a few of treatment days of treatment Male human Enlarged 30 droplets Reduced need Loss of a prostate to urinate feeling of during painful nighttime after pressure a few days of treatment Female Dog Unknown About 15 Size of the Lumps cancer with droplets per lump reduced disappeared by day lumps in the to about half next chest within weeks appointment The above results are illustrative to show that the extract is effective to prevent cancer cell proliferation also in vivo. Cancer types that seem to be affected comprise at least breast cancer, brain cancer, and colon cancer. The extract is effective generally in mammals. There is also evidence that administering the composition topically (spray or ointment) heals burning injuries on skin caused by radiation treatment.
Topical administration can also be used as a preventive measure for injuries caused by radiation treatments.
Claims (23)
1. A composition for suppressing mammalian cancer cell proliferation or growth, the composition being a solution comprising an alcoholic lignan extract or a mixture of alcoholic lignan extracts from one or more of coniferous species selected from the group of genus consisting of Picea, Abies, and Pinus, and optionally betulonic or betulinic acid, wherein the lignan extract or mixture of lignan extracts comprises at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers and a fraction containing various oligolignans.
2. The composition of claim 1, wherein the alcoholic extract or the mixture of alcoholic lignan extracts comprises lower mono- or/and dialcohols, such as ethanol or propanediol.
3. The composition of claim 1 or 2 wherein the composition comprises 5-50 wt% of the lignan extract and concentration of said lignans in the alcoholic lignan extract or in the mixture of alcoholic lignan extracts is:
-7-hydroxymatairesinol 70-80 wt%;
-conidendrin 3-8 wt%;
-lariciresinol 1-4 wt%;
-liovil 2-5 wt%;
-secoisolariciresinol 3-7 wt%; and -other lignans 0 -3 wt%.
-7-hydroxymatairesinol 70-80 wt%;
-conidendrin 3-8 wt%;
-lariciresinol 1-4 wt%;
-liovil 2-5 wt%;
-secoisolariciresinol 3-7 wt%; and -other lignans 0 -3 wt%.
4. The composition according to any of the previous claims, wherein the composition additionally comprises one or more lignans or sesquiterpene(s) at a range of 0-10 wt% selected from the group consisting of pinoresinol, nortrachelogenin, matairesinol, juvabiones, their geometric isomers or stereoisomers, and oligolignans.
5. The composition according to any one of previous claims, wherein the composition is for suppressing cancer cell proliferation and/or growth in an early phase in a mammal having diagnosed with melanoma, a brain cancer tumor, a colon cancer tumor, a breast cancer tumor, or a prostate cancer tumor.
6. The composition of any one of claims 1-4, wherein the composition comprises 1 0-1 50 M betulinic or betulonic acid.
7. The composition of claim 6, wherein the composition is for suppressing mammalian melanoma or prostate cancer cell proliferation.
8. The composition according to anyone of previous claims, wherein the composition is for suppressing cancer cell proliferation and/or growth in combination with chemotherapy and/or radiation.
9. The composition according to claim 1 for topical use in treating or preventing burning injuries and skin injuries.
10. A composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from the group of genuses consisting of Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid from bark of Betula sp. for use in suppressing cancer cell proliferation and/or growth in a mammal, wherein said extract or mixture of extracts comprises at least the following lignans:
hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers and a fraction containing various oligolignans.
hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers and a fraction containing various oligolignans.
11. A composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid from bark of Betula sp. for use in suppressing cancer cell proliferation and/or growth in a mammal according to claim 10, wherein the composition comprises 5-50 wt% of the lignan extract and concentration of said lignans in the lignan extract or the mixture of extracts is 7-hydroxymatairesinol 70-80 wt%;
conidendrin 3-8 wt%; lariciresinol 1-4 wt%; liovil 2-5 wt%;
secoisolariciresinol 3-7 wt%;
and other lignans 0-3 wt%.
conidendrin 3-8 wt%; lariciresinol 1-4 wt%; liovil 2-5 wt%;
secoisolariciresinol 3-7 wt%;
and other lignans 0-3 wt%.
12. A composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid from bark of Betula sp. for use in suppressing cancer cell proliferation and/or growth in a mammal according to claim 10 or 11, wherein the lignan extract is an alcoholic lignan extract or the mixture of alcoholic lignan extracts, which comprises lower mono- or/and dialcohols, such as ethanol or propanediol.
13. A composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid from bark of Betula sp. for use in suppressing cancer cell proliferation and/or growth in a mammal according to any one of the claims - 12, wherein the cancer cells are selected from the group consisting of melanoma cells, brain cancer cells, colon cancer cells, breast cancer cells, and prostate cancer tu mor.
14. A composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid from bark of Betula sp. for use in suppressing cancer cell proliferation and/or growth in a mammal according to claim 13, wherein a daily intake amounts 20 to 250 mg, more preferably to 50 to 200 mg and most preferably to 100-200 mg of 7- hydroxymatairesinol along with other lignans selected from the group of conidendrin, lariciresinol, liovil and secoisolariciresinol, and oligolignans
15. A composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid from bark of Betula sp. for use in suppressing cancer cell proliferation and/or growth in a mammal according to claim 14, wherein the daily intake of the extract is such that it contains 100-200 mg of 7-hydroxymatairesinol, 4-8 mg each of the following lignans secoisolariciresinol, condendrin, liovil, lariciresinol, and 4-20 mg other lignans including oligolignans.
16. A composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus and betulonic acid or betulinic acid from bark of Betula sp. for use in suppressing cancer cell proliferation and/or growth in a mammal according claim 11, wherein the composition comprises of 1 0-1 50 ILIM betulonic acid or betulinic acid.
17. A composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid from bark of Betula sp. for use in suppressing cancer cell proliferation and/or growth in a mammal according to claim 16, wherein the cancer cells are melanoma or prostate cancer cells.
18. A composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid from bark of Betula sp.for use in suppressing cancer cell proliferation and/or growth in a mammal according to anyone of claims 9-16, wherein the use is further combined in traditional cancer treatments, such as chemotherapy or radiation treatments.
19. A method for suppressing proliferation of prostate and melanoma cancer cells in vitro, comprising a step of adding on the prostate or melanoma cell culture a composition comprising a lignan extract or a mixture of lignan extracts from one or more of coniferous species selected from genus Picea, Abies, and Pinus and optionally betulonic acid or betulinic acid, and comprising at least the following lignans: 7-hydroxymatairesinol, conidendrin, lariciresinol, liovil and secoisolariciresinol or their geometric isomers or stereoisomers.
20. The method of claim 19, wherein the composition comprises the lignan extract or a mixture of the lignan extracts and betulonic acid or betulinic acid, and suppressing effect of the composition is synergistic as compared to an effect of the extract or mixture of extracts and betulinic or betulonic acids separately.
21. The method of claim 19, wherein the lignan extract or the mixture of the lignan extracts is an alcoholic lignan extract or the mixture of alcoholic lignan extracts which comprises lower mono- or/and dialcohols, such as ethanol or propanediol.
22. The method of claim 19, wherein the composition comprises 5-50 wt% of the lignan extract and concentration of said lignans in the lignan extract is:
-7-hydroxymatairesinol 70-80 wt%;
-conidendrin 3-8 wt%;
-lariciresinol 1-4 wt%;
-liovil 2-5 wt%;
-secoisolariciresinol 3-7 wt%; and -other lignans 0 -3 wt%.
-7-hydroxymatairesinol 70-80 wt%;
-conidendrin 3-8 wt%;
-lariciresinol 1-4 wt%;
-liovil 2-5 wt%;
-secoisolariciresinol 3-7 wt%; and -other lignans 0 -3 wt%.
23. A
method for preparing a composition of claim 1 for suppressing mammalian cancer cell profileration or growth, said method comprising following steps:
-extracting alcoholic solution of 5-50 wt % of the lignan extract or the mixture of alcoholic lignan extracts with a lower alcohol from one or more of coniferous species selected from genus Picea, Abies, and Pinus; and -admixing betulonic acid or betulinic acid preferably obtained from bark of Betula pendula into the alcoholic solution of lignan extract or the mixture of alcoholic lignan extracts..
method for preparing a composition of claim 1 for suppressing mammalian cancer cell profileration or growth, said method comprising following steps:
-extracting alcoholic solution of 5-50 wt % of the lignan extract or the mixture of alcoholic lignan extracts with a lower alcohol from one or more of coniferous species selected from genus Picea, Abies, and Pinus; and -admixing betulonic acid or betulinic acid preferably obtained from bark of Betula pendula into the alcoholic solution of lignan extract or the mixture of alcoholic lignan extracts..
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20195656 | 2019-08-02 | ||
FI20195656 | 2019-08-02 | ||
FI20205195 | 2020-02-26 | ||
FI20205195A FI130120B (en) | 2019-08-02 | 2020-02-26 | A method and a compound for preventing mammalian cancer cell proliferation and for treating cancer |
PCT/FI2020/050513 WO2021023914A1 (en) | 2019-08-02 | 2020-08-03 | A method and a compound for preventing mammalian cancer cell proliferation and for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3149681A1 true CA3149681A1 (en) | 2021-02-11 |
Family
ID=74503731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3149681A Pending CA3149681A1 (en) | 2019-08-02 | 2020-08-03 | A method and a compound for preventing mammalian cancer cell proliferation and for treating cancer |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4007587A4 (en) |
AU (1) | AU2020326319A1 (en) |
CA (1) | CA3149681A1 (en) |
WO (1) | WO2021023914A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113620912B (en) * | 2021-10-12 | 2021-12-28 | 江西省药品检验检测研究院 | Furanone compound and preparation method and application thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6689809B2 (en) * | 1999-03-30 | 2004-02-10 | Hormos Nutraceutical Oy Ltd. | Food additive or product or a pharmaceutical preparation, comprising hydroxymatairesinol |
FI20011194A0 (en) * | 2001-06-06 | 2001-06-06 | Bjarne Holmbom | A method for isolating chemicals from wood |
EP1687326A2 (en) * | 2003-11-10 | 2006-08-09 | Regents Of The University Of Minnesota | Method for obtaining natural products from plant material |
FI20080112A0 (en) * | 2008-02-14 | 2008-02-14 | Oy Granula Ab Ltd | Mixture |
US8496974B2 (en) * | 2008-11-25 | 2013-07-30 | Oy Granula Ab Ltd | Method for preparing a composition comprising a compound mixture and a carrier agent |
FI20106293A0 (en) * | 2010-12-06 | 2010-12-06 | Emilia Peuhu | New pharmaceutical compositions |
WO2014083171A1 (en) * | 2012-11-30 | 2014-06-05 | Harmonic Pharma | Natural compounds for use in the treatment of beta-2 adrenergic receptor related diseases |
EP3386524A1 (en) * | 2015-12-09 | 2018-10-17 | Oy Granula Ab Ltd | The use of a composition for lowering cholesterol level in a mammal, a method for its preparation, a composition and a method for preparing food additive comprising said composition |
FR3053251A1 (en) * | 2016-07-01 | 2018-01-05 | Tomcat International Limited | COMPOSITION FOR COMBATING THE SIGNS OF SKIN AGING AND PHANESIS |
-
2020
- 2020-08-03 CA CA3149681A patent/CA3149681A1/en active Pending
- 2020-08-03 AU AU2020326319A patent/AU2020326319A1/en active Pending
- 2020-08-03 EP EP20850158.5A patent/EP4007587A4/en active Pending
- 2020-08-03 WO PCT/FI2020/050513 patent/WO2021023914A1/en active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
EP4007587A4 (en) | 2023-09-27 |
EP4007587A1 (en) | 2022-06-08 |
WO2021023914A1 (en) | 2021-02-11 |
AU2020326319A1 (en) | 2022-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jagtap et al. | Artocarpus: A review of its traditional uses, phytochemistry and pharmacology | |
Prakash et al. | Bioactive chemical constituents from pomegranate (Punica granatum) juice, seed and peel-a review | |
TWI735779B (en) | Composition for treating skin pigmentation and related methods | |
KR20200033241A (en) | Composition for anti-oxidation, anti-inflammation or inhibiting of osteoclast differentiation | |
WO2016060249A1 (en) | Tie2 activator containing olive fruit extract | |
CA3149681A1 (en) | A method and a compound for preventing mammalian cancer cell proliferation and for treating cancer | |
FI130120B (en) | A method and a compound for preventing mammalian cancer cell proliferation and for treating cancer | |
US20210030673A1 (en) | Method and a Compound for Preventing Mammalian Cancer Cell Proliferation and for Treating Cancer | |
KR20170023910A (en) | Pharmaceutical Compositions for Prevention or Treatment of nonalcoholic fatty liver disease Comprising Quercetin-3-O-glucoside | |
JP4675781B2 (en) | Adipocyte differentiation inhibitor | |
Farid et al. | Polyphenolic and flavonoids content, HPLC profiling and antioxidant activity of some medicinal plants with pancreatic histological study in alloxan-induced diabetic rats model. | |
Kumar et al. | A Review On Therapeutic Potential Of Punica Granatum. | |
US10765712B2 (en) | Use of a composition for lowering cholesterol level in a mammal, a method for its preparation and a product and a food additive comprising said composition | |
KR101469201B1 (en) | A COMPOSITION COMPRISING EXTRACT OF Laminaria japonica OR PORPYRIN-RELATED COMPOUNDS ISOLATED THEREFROM PREVENTING OR TREATING DIABETIC COMPLICATION | |
Ha et al. | Cytoprotective activity of lotus (Nelumbo nucifera Gaertner) leaf extracts on the mouse embryonic fibroblast cell | |
KR101469961B1 (en) | Method for separating porpyrin-related compounds from laminaria japonica for use in the prevention or treatment of diabetic complication | |
Khadka et al. | Pharmacognostic and pharmacological review on Choerospondias axillaris | |
KR102214014B1 (en) | Antioxidant or anticancer composition comprising extract of Osmanthus heterophylla leaf | |
Shandil | ANTI-OXIDANT, ANTI-HYPERTENSIVE, ANTI-DIABETIC AND ANTI-GLYCATION ACTIVITIES OF FERMENTED FRUIT JUICE OF MORINDA CITRIFOLIA (NONI) | |
KR100783205B1 (en) | The preparation containing coriolus versicolor extract and its polysaccharides having anti-hepatocytic activity | |
Rakesh et al. | A Review on Pharmacological Aspects of Phlorotannins derived from Brown Algae | |
KR20220056612A (en) | Compositions for the prevention or treatment of obesity or diabetes mellitus and method for producing the same | |
KR20160008132A (en) | Composition for preventing or treating of oxidative brain injury and brain function disorder | |
KR20150061506A (en) | Composition comprising γ-oryzanol derived from danmi | |
KR20230056234A (en) | A composition for improving metabolic syndrome-related diseases caused by endocrine disruptors comprising cirsium setidens extract |